Veriteq (DIGA) 10-K/A 19 Aug 14 2013 FY Annual report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Apr. 10, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'VERITEQ	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	9,936,464	'
Entity Public Float	'	'	$1,500,000
Amendment Flag	'true	'	'
Amendment Description	'This Amendment No. 1 on Form 10-K/A amends our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission on April 15, 2014 (the "Original Report") and is being filed for the purpose of correcting information in Part I, Items 1 and 1A., Part II, Items 7, 8 and 9A and Part IV, Item 15. In connection with the preparation of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2014, the Company identified an error relating to the accounting for the financing transaction described below. On November 13, 2013, the Company entered into a financing transaction, as more fully discussed in Note 5, which included notes in the principal amount of $1,816,667. The notes are convertible into shares of the Company's common stock at an initial exercise price of $0.75 per share. The notes provided for the initial conversion price to be reset to lower amounts in the event the Company issues its common stock or is deemed to have issued its common stock at a price below the conversion price in effect at that time. This provision results in what is referred to as an embedded derivative and should have been bifurcated and a liability recorded for the embedded derivative at fair value upon the issuance of the notes and on December 31, 2013 in the Original Report. This oversight resulted in an understatement of the derivative liability of $3.1 million at December 31, 2013. Accordingly, we are restating our previously filed financial statements to reflect the fair value of this embedded derivative liability as a non-cash current liability on our Consolidated Balance Sheet at December 31, 2013 and to reflect the initial fair value and change in the fair value through December 31, 2013 in our Consolidated Statement of Operations, Consolidated Statement of Comprehensive Losses, Consolidated Statement of Changes in Stockholders' Deficit and Consolidated Statement of Cash Flows for the year ended December 31, 2013 and from December 14, 2011 (our inception date) to December 31, 2013. We are also restating certain unaudited pro forma results related to a business combination for the year ended December 31, 2013. The correction of the error did not impact any assets. The effect of the restatement on each of our financial statements at and as of December 31, 2013 and for the period from December 14, 2011 (Inception) to December 31, 2013 as well as certain unaudited pro forma information for the year ended December 31, 2013 is as follows:	'	'
Entity Central Index Key	'0000924642	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
ASSETS	'	'
Cash	$13	$183
Restricted cash	882	'
Inventory	21	'
Other receivable	171	'
Other current assets	96	'
Total current assets	1,183	183
Property and equipment, net	4	'
Other assets	14	'
Intangible assets, net	7,018	7,612
Total assets	8,219	7,795
LIABILITIES AND STOCKHOLDERS’ DEFICIT	'	'
Notes payable, net of discounts (including $60 and $232 to related parties, respectively)	467	326
Liabilities for conversion options of convertible notes	3,124	0
Accounts payable	854	82
Accrued expenses (including $1,764 and $724 to related parties, respectively)	2,718	1,072
Due to related party under shared services agreement	211	138
Total current liabilities	7,374	1,618
Commitments and contingencies	'	'
Note payable to related party, net of discount	'	78
Subordinated convertible debt with an embedded convertible option, at fair value	4,925	2,137
Warrant liabilities	6,114	'
Contingent consideration – Estimated royalty obligations	3,940	4,000
Total liabilities	22,353	7,833
Preferred Stock ($10 par value; shares authorized 5,000; 0 shares issued and outstanding)	'	'
Common shares ($0.01 par value; shares authorized 50,000; shares issued and outstanding, 9,459 and 7,021, respectively)	95	70
Additional paid-in-capital	5,595	1,515
Accumulated deficit during the development stage	-19,824	-1,623
Total stockholders’ deficit	-14,134	-38
Total liabilities and stockholders’ deficit	$8,219	$7,795

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Notes payable, net of discounts to related parties (in Dollars)	$60	$232
Accrued expenses to related parties (in Dollars)	$1,764	$724
Preferred shares, par value (in Dollars per share)	$10	$10
Preferred shares, shares authorized	5,000,000	5,000,000
Preferred shares,shares outstanding	0	0
Preferred Shares, shares issued	0	0
Common shares, par value (in Dollars per share)	$0.01	$0.01
Common shares, shares authorized	50,000,000	50,000,000
Common shares, shares issued	9,459,000	7,021,000
Common shares, shares outstanding	9,459,000	7,021,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended				25 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013
Sales	$18,000		'		$18,000
Cost of goods sold	7,000		'		7,000
Gross margin	11,000		'		11,000
Operating Expenses:	'		'		'
Selling, general and administrative expenses	5,994,000		2,064,000		8,076,000
Depreciation and amortization expense	595,000		208,000		803,000
Total operating expenses	6,589,000		2,272,000		8,879,000
Other expense	4,527,000		'		4,527,000
Interest expense	7,096,000		133,000		7,229,000
Loss before income taxes	-18,201,000		-2,405,000		-20,624,000
Benefit for income taxes	0		800,000		800,000
Net loss	($18,201,000)		($1,605,000)		($19,824,000)
Net loss per common share — basic and diluted (in Dollars per share)	($2.11)		($0.25)		'
Weighted average number of common shares outstanding — basic and diluted (in Shares)	8,607	[1],[2]	6,529	[1],[2]	'
[1]	Basic and diluted loss per common share has been computed by dividing the loss by the weighted average number of common shares outstanding.
[2]	The following stock options and warrants and shares issuable upon conversion of convertible notes payable outstanding at December 31, 2013 and 2012 were not included in the computation of dilutive loss per share because the net effect would have been anti-dilutive:

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	1 Months Ended	12 Months Ended				25 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013
Net loss	($18)	($18,201)		($1,605)		($19,824)
Comprehensive loss	'	($18,201)	[1]	($1,605)	[1]	($19,824)	[1]
[1]	During the quarter ended December 31, 2013, we reclassified $54 thousand related to the unrealized loss on of marketable securities held for sale from otheraccumulated comprehensive loss to net loss as a result of the sale of the marketable securities in November 2013.

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Stockholders’ Deficit (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit during Development Stage [Member]

Accumulated Deficit during Development Stage [Member]

Accumulated Deficit during Development Stage [Member]

VeriTeQ Corporation [Member]

Investors [Member]

September 2012 [Member]

October 2012 [Member]

December 2012 [Member]

March 2013 [Member]

June 2013 [Member]

July 2013 [Member]

October 2013 [Member]

November 2013 [Member]

Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

VeriTeQ Corporation [Member]

Investors [Member]

March 2013 [Member]

June 2013 [Member]

July 2013 [Member]

October 2013 [Member]

November 2013 [Member]

VeriTeQ Corporation [Member]

Investors [Member]

September 2012 [Member]

October 2012 [Member]

December 2012 [Member]

March 2013 [Member]

June 2013 [Member]

July 2013 [Member]

October 2013 [Member]

November 2013 [Member]

Net loss

($18,201,000)

($1,605,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

($18,000)

($18,201,000)

($1,605,000)

'

'

'

'

'

'

'

'

'

'

Issuance of restricted stock for compensation, January 2013

1,400,000

'

'

'

'

'

'

'

9,000

'

'

'

'

'

'

'

'

-9,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of restricted stock for compensation, January 2013 (in Shares)

900,000

'

'

'

'

'

'

'

859,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuances of common stock for founders shares, January 2012

'

'

'

'

'

'

'

'

'

56,000

'

'

'

'

'

'

'

'

-56,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuances of common stock for founders shares, January 2012 (in Shares)

'

'

'

'

'

'

'

'

'

5,563,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for acquisition

'

760,000

4,108,000

-82,000

-4,026,000

'

10,000

'

'

8,000

'

'

'

'

'

925,000

'

'

752,000

'

'

'

'

'

'

'

'

'

'

'

935,000

'

'

'

'

'

'

'

'

'

Issuance of common stock for acquisition (in Shares)

'

'

411,000

-8,215,000

'

'

1,029,000

'

'

763,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

25,000

80,000

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

15,000

25,000

78,000

'

'

'

'

'

'

'

'

'

'

'

'

15,000

'

'

'

'

'

'

'

'

Issuance of common stock (in Shares)

'

'

'

'

'

'

'

41,000

19,000

218,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for services

'

160,000

'

'

'

'

'

'

'

4,000

'

'

1,000

1,000

1,000

'

'

'

156,000

'

'

'

'

'

62,000

90,000

262,000

'

'

'

'

'

'

'

'

'

'

63,000

91,000

263,000

Issuance of common stock for services (in Shares)

'

'

'

'

'

'

'

'

'

436,000

'

'

42,000

33,000

130,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock from conversion of preferred stock, October 2013

'

'

'

'

'

-4,108,000

'

'

82,000

'

'

'

'

'

'

'

'

4,026,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock from conversion of preferred stock, October 2013 (in Shares)

'

'

'

'

'

-411,000

'

'

8,215,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjust for cash paid in lieu of fractional shares, October 2013

-16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjust for cash paid in lieu of fractional shares, October 2013 (in Shares)

'

'

'

'

'

'

'

'

-7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for conversion of debt

'

'

'

'

'

'

'

'

'

'

1,000

2,000

'

'

'

'

'

'

'

33,000

34,000

41,000

194,000

439,000

'

25,000

'

'

'

'

'

'

33,000

34,000

41,000

195,000

441,000

'

25,000

'

Issuance of common stock for conversion of debt (in Shares)

'

'

'

'

'

'

'

'

'

'

95,000

221,000

'

17,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of warrants in connection with note payable, April 2013

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beneficial conversion feature of convertible note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,000

34,000

41,000

'

'

'

'

'

'

'

'

'

'

33,000

34,000

41,000

'

'

'

'

'

Share-based compensation

2,048,000

354,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,048,000

354,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, December 31

-38,000

-18,000

'

'

'

'

'

'

70,000

'

'

'

'

'

'

'

'

1,515,000

'

'

'

'

'

'

'

'

'

'

-1,623,000

-18,000

'

'

'

'

'

'

'

'

'

'

Balance, December 31 (in Shares)

'

'

'

'

'

'

'

'

7,021,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, December 31

($14,134,000)

($38,000)

'

'

'

'

'

'

$95,000

$70,000

'

'

'

'

'

'

'

$5,595,000

$1,515,000

'

'

'

'

'

'

'

'

($18,000)

($19,824,000)

($1,623,000)

'

'

'

'

'

'

'

'

'

'

Balance, December 31 (in Shares)

'

'

'

'

'

'

'

'

9,459,000

7,021,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities:	'	'	'
Net loss	($18,201,000)	($1,605,000)	($19,824,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Share based compensation	2,048,000	354,000	2,402,000
Depreciation and amortization	595,000	208,000	803,000
Non-cash interest expense	6,634,000	118,000	6,752,000
Change in fair value of subordinated convertible debt	2,788,000	'	2,788,000
Change in fair value of conversion options of convertible notes	363,000	0	363,000
Change in fair value of warrants	720,000	'	720,000
Deferred income tax benefit	'	-800,000	-800,000
Change in accounts payable, accrued expenses and liability under shared services agreement	2,053,000	1,413,000	3,485,000
Change in other assets	-10,000	'	-10,000
Net cash used in operating activities	-1,954,000	-312,000	-2,266,000
Cash flows from investing activities:	'	'	'
Purchases of fixed assets	-4,000	'	-4,000
Sale of marketable securities, available-for-sale	133,000	'	133,000
Cash acquired from acquisition of VeriTeQ Corporation (f/k/a Digital Angel Corporation)	818,000	'	818,000
Net cash provided by investing activities	947,000	'	947,000
Cash flows from financing activities:	'	'	'
Proceeds from the issuances of notes payable and warrants, net of repayments of $100 in 2013	60,000	400,000	460,000
Proceeds from the issuance of common stock to investors	25,000	80,000	105,000
Proceeds from the issuance of senior convertible debt	1,650,000	'	1,650,000
Change in restricted cash	-882,000	'	-882,000
Cash paid in lieu of fractional shares	-16,000	'	-16,000
Proceeds from the issuance of common stock and warrants to investor	'	15,000	15,000
Net cash provided by financing activities	837,000	495,000	1,332,000
Net (decrease) increase in cash	-170,000	183,000	13,000
Cash --- Beginning of period	183,000	'	'
Cash — End of period	13,000	183,000	13,000
Common Stock [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Issuance of common stock for investment advisory and investor relation services	417,000	'	416,000
Realized loss on sale of marketable securities, available-for-sale	107,000	'	107,000
Change in other receivable	54,000	'	54,000
Change in other current assets	-72,000	'	-72,000
Warrant [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Issuance of warrants for contract amendment	$550,000	'	$550,000

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parentheticals) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Repayments of notes payable and warrants	$100

Note_1_Organization_and_Summar

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	1. Organization and Summary of Significant Accounting Policies
	These consolidated financial statements and notes thereto, include the financial statements of VeriTeQ Corporation (“VC”), formerly known as Digital Angel Corporation, and its wholly-owned subsidiary, VeriTeQ Acquisition Corporation (“VAC”), a Florida corporation formed on December 14, 2011. VC became the legal acquirer of VAC and VAC became the accounting acquirer of VC pursuant to the terms of a share exchange agreement (the “Exchange Agreement”), as more fully discussed below. In January 2012, VAC acquired all of the outstanding stock of PositiveID Animal Health Corporation, a Florida corporation, from PositiveID Corporation (“PSID”), a related party. In December 2012, VAC formed a subsidiary, VTQ IP Holding Corporation, a Delaware corporation. VC, VAC and VAC’s subsidiaries are referred to together as, “VeriTeQ,” “the Company,” “we,” “our,” and “us”. Our business consists of ongoing efforts to provide implantable medical device identification and radiation dose measurement technologies to the healthcare industry.
	Going Concern
	The accompanying financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We are in the development stage, have incurred operating losses since our inception and have a working capital deficit. Failure to raise capital to fund our operations and generate positive cash flow to fund such operations will have a material adverse effect on our financial condition. These factors raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from this uncertainty.
	We need to raise additional funds to fund our operations till we begin to ship our products and we may not be able to obtain debt or equity funding at all or if available, they may not be on favorable terms.
	Although we had negative working capital at December 31, 2013, we are hopeful that we will be able to generate enough cash from capital raises, business operations as we begin to ship our products, additional issuances of promissory notes to related parties and others and through other investing and financing sources as well as from our ability to delay certain salary and bonus payments to senior management until funds are available and to undertake other cash management initiatives, including working with our vendors to continue to allow us to extend payment terms in order to operate our business for the twelve months ending December 31, 2014. In November 2013, we entered into a $1,816,667 convertible debt financing as more fully described in Note 5, which matures on November 13, 2014. Under the terms of the financing, $750,000 of the proceeds were required to be placed in restricted bank accounts. In addition, $132,500 of proceeds from the sale of marketable securities that we sold under the terms of a securities purchase agreement with one of the investors was required to be placed in the restricted accounts. Thus, the restricted funds totaled $0.9 million at December 31, 2013. Per the terms of the financing, the restricted funds were to be applied to pay any redemption or other payments due under the applicable note to the applicable holder from time to time with a portion of the restricted funds to be released to us upon any conversion of the notes or at any time the balance of the funds placed in the restricted accounts by the note holders exceeds the principal of the applicable note then outstanding. However, to provide the Company with additional liquidity, on April 3, 2014, certain investors allowed the transfer of approximately $145,000 of the restricted funds to our operating account.
	Our goal is to achieve profitability and to generate positive cash flows from operations. Our capital requirements depend on a variety of factors, including but not limited to, the cash that will be required to grow our business operations and to service our debt. Failure to have the funds held in the restrictive bank accounts released to us, to raise additional capital to fund our operations and to generate positive cash flow from such operations will have a material adverse effect on our financial condition, results of operations and cash flows.
	Share Exchange Agreement and Reverse Stock Split
	On June 24, 2013, VAC and its stockholders entered in the Exchange Agreement with VC and the closing of the transaction (the “VeriTeQ Transaction”) took place on July 8, 2013 (the “Closing Date”). Pursuant to the terms of the Exchange Agreement, VAC exchanged all of its issued and outstanding shares of common stock for 4,107,592 shares of VC’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”). On July 10, 2013, VC realized that it incorrectly issued the Series B Preferred Stock and as result, on July 12, 2013, it exchanged the Series B Preferred Stock for 410,759 shares of its newly created Series C convertible preferred stock, par value $10.00 (the “Series C Preferred Stock”). The terms of the Series C Preferred Stock are substantially similar to the Series B Preferred Stock, including the aggregate number of shares of common stock into which the Series C Preferred Stock was convertible. Each share of Series C Preferred Stock was convertible into twenty shares of VC’s common stock, par value $0.01 per share (the “Conversion Shares”), automatically upon the effectiveness of the Reverse Stock Split (defined below) on October 18, 2013 (such transaction is sometimes referred to herein as the “Share Exchange”).
	In addition, all outstanding stock options to purchase shares of VAC’s common stock, whether or not exercisable or vested, converted into options to acquire shares of VC’s common stock (the “Substitute Options”), and all outstanding warrants to purchase shares of VAC’s common stock converted into warrants to purchase shares of VC’s common stock (the “Converted Warrants”). As a result of the Share Exchange and the issuance of the Substitute Options and the Converted Warrants, VAC became a wholly-owned subsidiary of VC, and VAC’s shareholders owned on July 12, 2013 approximately 91% of VC’s common stock, on an as converted, fully diluted basis (including outstanding stock options and warrants).
	Based on the terms of the transaction, VAC was the accounting acquirer and as a result VAC’s operating results became the historical operating results of the Company. In addition, VAC’s common stock has been presented as if it was converted into shares of VC’s common stock at the beginning of the periods presented herein and based on the exchange ratio under the terms of the Exchange Agreement, which was .19083. The exchange ratio took into consideration the Reverse Stock Split, which is more fully discussed below.
	The Series C Preferred Stock consisted of 500,000 authorized shares, 410,759 of which were issued and outstanding through October 17, 2013. The shares of Series C Preferred Stock issued to VAC’s shareholders in connection with the Share Exchange, by their principal terms:
	(a)	converted into a total of 8,215,184 Conversion Shares, constituting approximately 88% of the issued and outstanding shares of common stock of VC, following the Reverse Stock Split on October 18, 2013 (as more fully discussed below);
	(b)	had the same voting rights as holders of VC’s common stock on an as-converted basis for any matters that are subject to stockholder vote;
	(c)	were not entitled to any dividends; and
	(d)	were to be treated pari passu with the common stock on liquidation, dissolution or winding up of VC.
	On July 12, 2013, VC obtained approval from a majority of its shareholders for and to effect a one for thirty (1:30) reverse stock split (the “Reverse Stock Split”). On October 18, 2013, VC filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Reverse Stock Split became effective on October 18, 2013. The Reverse Stock Split caused the total number of shares of common stock outstanding, including the shares underlying the Series C Preferred Stock, to equal 9,302,674 shares of VC common stock based on the shares outstanding on October 18, 2013. The Reverse Stock Split did not affect the number of shares of VC’s authorized common stock, which remain at 50 million shares.
	As a result of the Reverse Stock Split, all share information in this Annual Report has been restated to reflect the Reverse Stock Split as if it had occurred at the beginning of the periods presented, where appropriate.
	In connection with the Share Exchange, Digital Angel Corporation changed its name to VeriTeQ Corporation effective October 18, 2013.
	On July 12, 2013, pursuant to the Exchange Agreement, a majority of VC’s voting stockholders adopted resolutions by written consent approving the Digital Angel Corporation 2013 Stock Incentive Plan (the “DAC 2013 Stock Plan”), under which employees, including officers and directors, and consultants may receive awards. The Plan became effective on October 18, 2013.
	The Company is in the development stage as defined by Accounting Standards Codification subtopic 915-10 Development Stage Entities ("ASC 915-10") and its success depends on its ability to obtain financing and realize its marketing efforts. To date, the Company has generated only a small of revenue, has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from December 14, 2011 (Inception) through December 31, 2013, the Company has accumulated losses of approximately $17 million.
	Summary of Significant Accounting Policies
	Principles of Consolidation
	The financial statements include our accounts and the accounts of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America (“U.S.”) requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on the knowledge of current events and actions we may undertake in the future, they may ultimately differ from actual results. Included in these estimates are assumptions used in determining the lives of long-lived assets, in Black-Scholes-Merton (“BSM”) valuation models in estimating the fair value of stock-based compensation, promissory notes with an embedded convertible options and royalty obligations and in determining valuation allowances for intangible assets, deferred tax assets, among others.
	Concentration of Credit Risk
	We maintained our domestic cash in two financial institutions during the year ended December 31, 2013. Balances were insured up to Federal Deposit Insurance Corporation limits of $250,000 per institution. At times, cash balances may exceed the federally insured limits.
	Inventory
	Inventory consisted of purchased finished goods at December 31, 2013. We did not have inventory on hand at December 31, 2012. Inventory is valued at the lower of the value using the first-in, first-out (“FIFO)” cost method, or market.
	Property and Equipment
	Property and equipment, consisting primarily of computer equipment, and are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful life of the related assets (generally three years for computer equipment and 10 years for other equipment). Depreciation expense for the years ended December 31, 2013 and 2012 was approximately $1,000 and nil, respectively.
	Intangible Assets
	We account for intangible assets in accordance with the Intangibles — Goodwill and Other Topic of the Codification. Intangible assets deemed to have an indefinite life, such as goodwill, are reviewed at least annually for impairment. Intangible assets with finite lives are amortized over their estimated useful lives. We do not have any intangible assets with indefinite lives.
	We have intangible assets consisting of technology, customer relationship and trademarks, which are more fully discussed in Note 2 and 3. These intangible assets are amortized over their expected economic lives ranging from 7 to 14 years. The lives were determined based upon the expected use of the asset, the ability to extend or renew patents, trademarks and other contractual provisions associated with the asset, the stability of the industry, expected changes in and replacement value of distribution networks and other factors deemed appropriate. We continually evaluate whether events or circumstances have occurred that indicate the remaining estimated useful lives of our definite-lived intangible assets warrant revision or that the remaining balance of such assets may not be recoverable. We use an estimate of the related undiscounted cash flows over the remaining life of the asset in measuring whether the asset is recoverable. We believe that no impairment of our intangible assets existed as of December 31, 2013.
	Stock-Based Compensation
	At December 31, 2013, we had five stock-based employee compensation plans which are described more fully in Note 7. In accordance with the Compensation – Stock Compensation Topic of the Codification, awards granted are valued at fair value and compensation cost is recognized on a straight line basis over the service period of each award.
	Income Taxes
	We recognize of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of timing differences such as amortization of intangible assets, deferred officers' compensation and stock-based compensation. A valuation allowance is provided against net deferred tax assets where we determine realization is not currently judged to be more likely than not. We recognize and measure uncertain tax positions through a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. We consider many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes. Accordingly, we report a liability for unrecognized tax benefits resulting from the uncertain tax positions taken or expected to be taken in a tax return and recognize interest and penalties, if any, related to uncertain tax positions in income tax expense.
	Loss Per Common Share and Common Share Equivalent
	Basic and diluted loss per common share has been computed by dividing the loss by the weighted average number of common shares outstanding. Since we have incurred losses attributable to common stockholders, diluted loss per common share has not been computed by giving effect to all potentially dilutive common shares that were outstanding during the period. Dilutive common shares consist of incremental shares issuable upon exercise of stock options, warrants and convertible notes payable to the extent that the average fair value of our common stock for each period is greater than the exercise/conversion price of the derivative securities.
	Impact of Recently Issued Accounting Standards
	From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies will issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC” or “Codification”) are communicated through issuance of an Accounting Standards Update (“ASU”).
	In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, an amendment to FASB ASC Topic 220. The update requires disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This ASU was effective prospectively for our fiscal years, and interim periods within those years beginning after December 15, 2012. The adoption of this did not have a material impact on our financial statements.
	In July 2013, ASU ("2013-11"), Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists - a consensus of the FASB Emerging Issues Task Force, was issued to eliminate diversity in practice. ASU 2013-11 requires that companies net their unrecognized tax benefits against all same-jurisdiction net operating losses or tax credit carryforwards that would be used to settle the position with a tax authority. This new guidance is effective prospectively for annual reporting periods beginning on or after December 15, 2013 and interim periods therein. The adoption of ASU 2013-11 will not have a material effect on our consolidated financial statements because it aligns with our historical presentation.

Note_2_Acquisitions

Note 2 - Acquisitions	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	'
	2. Acquisitions
	Acquisition	Dates		Acquisition			Intangible		Description of Assets
		Acquired		Price			Assets
							Acquired
	(in thousands)
	PositiveID Animal Health Corporation	1/11/12		$	1,200		$	2,000	Implantable RFID medical device technologies
	Bio Sensor patents from PSID	8/28/12			—			—	Assignment of bio sensor patents
	Asset Purchase Agreement from SNC Holding Corp.	12/3/12		$	5,820		$	5,820	Radiation dose monitoring technology for healthcare industry
	VeriTeQ Corporation	7/8/13		$	935		$	—	Cash, marketable securities and receivables, among others
	PositiveID Animal Health Corporation acquired by VeriTeQ Acquisition Corporation
	On January 11, 2012, VAC entered into a stock purchase agreement with PSID to acquire the outstanding stock of PSID’s wholly-owned subsidiary, PositiveID Animal Health Corporation (“PAH”). Our chairman and chief executive officer is the former chairman and chief executive officer of PSID. In addition, the current chairman and chief executive officer of PSID was a member of our board of directors until July 8, 2013.
	Under the terms of the stock purchase agreement, VAC: (i) exchanged 0.8 million shares of its common stock, valued at approximately $0.3 million for the 5.0 million shares of outstanding stock of PAH; (ii) assumed the obligations under outstanding common stock options to acquire 6.9 million shares of PAH, which it converted into stock options to acquire 6.9 million shares of VAC’s common stock and on October 18, 2013, converted into approximately 1.3 million shares of VC’s common stock; (iii) issued a promissory note payable to PSID in the principal amount of $0.2 million with a stated interest rate of 5% per annum (the “PSID Note”); (iv) assumed obligations under an existing development and supply agreement ; and (v) agreed to make royalty payments to PSID as more fully discussed below. VAC recorded a discount on the PSID Note of $60 thousand using a discount rate of approximately 11.9%. The stock options assumed, which have an exercise price of $0.05 per share, after conversion into VC stock, were valued at $0.5 million based on the BSM valuation model using the following assumptions: expected term of 8.2 years, expected volatility of 126%, risk-free interest rate of 1.50%, and expected dividend yield of 0%.
	In connection with the acquisition, VAC entered into a license agreement with PSID (the “Original License Agreement”) which granted it a non-exclusive, perpetual, non-transferable, license to utilize PSID’s bio sensor implantable radio frequency identification (RFID) device that is protected under United States Patent No. 7,125,382, “Embedded Bio Sensor System” (the “Patent”) for the purpose of designing and constructing, using, selling and offering to sell products or services related to its business, but excluding the GlucoChip or any product or application involving blood glucose detection or diabetes management. Pursuant to the Original License Agreement, PSID was to receive royalties in the amount of 10% on all gross revenues arising out of or relating to VAC’s sale of products, whether by license or otherwise, specifically relating to the Patent, and a royalty of 20% on gross revenues that are generated under a development and supply agreement between PSID and Medical Components, Inc. (“Medcomp”) dated April 2, 2009. The total cumulative royalty payments under the agreement with Medcomp will not exceed $0.6 million.
	On June 26, 2012, the Original License Agreement was amended pursuant to which the license was converted from a non-exclusive license to an exclusive license, subject to VAC meeting certain minimum royalty requirements, which were amended during 2013 as more fully discussed in Note 10.
	The total purchase price of PAH was allocated as follows (in thousands):
	Intangible Assets:
	Technology	$	1,500
	Customer relationship		500
	Deferred tax liability		(800	)
	Net	$	1,200
	VAC paid for this acquisition as follows:
	4.0 million shares of common stock issued and assumption of PAH options	$	760
	Estimated royalty obligations		300
	Promissory note, net		140
		$	1,200
	Based on our estimates of the amount of royalty payments that we expect to pay under the MedComp agreement at the date of acquisition, we have accrued $0.3 million.
	In determining the purchase price for PAH, VAC considered various factors including: (i) projected revenue streams from the assets acquired; (ii) the potential revenue stream from the existing customer relationship; and (iii) the opportunity for expanded research and development of the product offerings and the potential for new product offerings.
	PAH had no business operations or process prior to the acquisition, and, accordingly, the acquisition was treated as an acquisition of assets and unaudited pro forma results of operations for the year ended December 31, 2012 is not presented. The assets acquired and consideration paid are recorded at their fair value on the date of the acquisition.
	See Note 10 for a discussion of a shared services agreement between VAC and PSID.
	Bio Sensor Patents acquired by VeriTeQ Acquisition Corporation
	On August 28, 2012, VAC entered into an Asset Purchase Agreement (the “APA”) with PSID, whereby it purchased all of the intellectual property, including patents and patents pending, related to the PSID’s embedded bio sensor portfolio of intellectual property. Under the APA, PSID is to receive royalties in the amount of ten percent (10%) on all gross revenues arising out of or relating to VAC’s sale of products, whether by license or otherwise, specifically relating to the embedded bio sensor intellectual property, to be calculated quarterly with royalty payments due within 30 days of each quarter end. Minimum royalty requirements, which were to begin in 2013 and thereafter through the remaining life of any of the patents and patents pending, were identical to the minimum royalties due under the Original License Agreement, as amended.
	Simultaneously with the APA, VAC entered into a license agreement with PSID granting PSID an exclusive, perpetual, transferable, worldwide and royalty-free license to the patent and patents pending that are a component of the GlucoChip in the fields of blood glucose monitoring and diabetes management. In connection with the APA, the Original License Agreement, as amended June 26, 2012, was terminated. Also on August 28, 2012, the PSID Security Agreement was amended, pursuant to which the assets sold by PSID to VAC under the APA and the related royalty payments were added as collateral under the PSID Security Agreement. We had no plans to develop or commercialize the Bio Sensor patents, and therefore, no value was ascribed to these patents. Further, we are not aware of a buyer or licensor for these patents.
	On July 8, 2013, we entered into a letter agreement with PSID, which modified the terms of the royalty payments due to PSID under the APA, and on November 8, 2013, we amended the July 8, 2013 letter agreement, as more fully discussed in Note 10.
	VeriTeQ Acquisition Corporation Asset Purchase Agreement with SNC Holding Corp.
	In December 2012, VAC entered into an asset purchase agreement and a royalty agreement with SNC Holding Corp. wherein VAC acquired various technology and trademarks related to its radiation dose measurement technology. Under the terms of the agreements, VAC issued a non-interest bearing secured subordinated convertible promissory note, in the principal amount of $3.3 million and agreed to make royalty payments based on a percentage of revenue earned from the technology acquired. In addition, under the terms of sublicense agreement related to the technology, VAC made a $20 thousand sublicense payment in February 2013 and agreed to make minimum sublicense payments aggregating $0.2 million over the period from June 2014 to March 2017. The promissory note is convertible into one-third of the beneficial stock ownership of VC held by our CEO, or approximately 2.2 million shares at December 31, 2013. The promissory note was recorded at its initial estimated fair value of approximately $2.1 million and is being re-valued at each reporting period with changes in the fair value recorded as other expense/income (see Notes 5 and 6 for a further discussion of the current fair value of the promissory note). The total purchase price, including estimated royalty obligations of $3.7 million, was approximately $5.8 million. In connection with the asset purchase agreement with SNC Holding Corp., VAC entered into a security agreement whereby certain intellectual property purchased thereunder, including intellectual property related to its dosimeter products, would revert to SNC Holding Corp. in the event of: (i) a default under the promissory note; (ii) failure to pay the minimum royalty obligations; (iii) failure to perform its obligations with respect to commercializing the intellectual property acquired; or (iv) the occurrence of an unauthorized issuance of VTQ IP Holding Corporation’s capital stock. The unamortized balance of the intellectual property related to our dosimeter products was $5.4 million as of December 31, 2013.
	The total purchase price of the assets acquired was allocated as follows (in thousands):
	Intangible Assets:
	Technology	$	5,370
	Trademarks		450
	Total	$	5,820
	VAC paid for this acquisition as follows:
	Estimated royalty obligations	$	3,700
	Note at fair value		2,100
	Assumption of liabilities		20
	Total	$	5,820
	The estimated fair value of the acquired intangible assets as presented above were determined using discounted cash flow methodology as more fully discussed in Note 3. The assets acquired and the consideration paid is recorded at their fair value on the date of acquisition.
	Acquisition of VeriTeQ Corporation under Share Exchange Agreement
	Given VAC’s former shareholders’ ownership in VC, as a result of the Exchange Agreement, VAC was considered to be the acquirer for accounting purposes and the transaction was accounted for as a reverse acquisition of VC by VAC under the accounting rules for business combinations. Accordingly, the accompanying unaudited condensed consolidated financial statements reflect VC’s assets and liabilities at fair value to the extent they are deemed to have been acquired for accounting purposes and VC has established a new basis for its assets and liabilities based upon the fair values thereof and the value of VC’s shares outstanding on July 8, 2013, the closing date. The value of VC’s common stock was calculated based on the closing price of VC’s common stock on July 8, 2013, which was $0.90 per share on a post reverse stock split basis. The value of VC’s outstanding stock options was based on the closing price of VC’s common stock on July 8, 2013 and using the BSM valuation model using the following assumptions: expected term of 2.6 years, expected volatility of 106.6 %, risk-free interest rate of 0.62%, and expected dividend yield of 0%
	In addition, the Exchange Agreement created a new measurement date for the valuation of the options to acquire shares of VAC’s common stock, which were converted into options to acquire shares of VC’s common stock. The new measurement date was the closing date of the transaction which was July 8, 2013. This new measurement did not result in a non-cash compensation charge because the value of the modified options did not exceed the value of the options before the modification.
	Total Purchase Price was calculated as follows (in thousands, except per share amount):
	Value of VC’s common stock outstanding on July 8, 2013 (1,029 shares @ $.90 per share)	$	926
	Value of VC’s stock options outstanding on July 8, 2013		9
	Total	$	935
	The total purchase price of the VC assets acquired and liabilities assumed was allocated was follows (in thousands):
	Assets purchased:
	Cash	$	818
	Marketable securities		239
	Current portion of other receivable		168
	Prepaid and other assets		47
	Fixed assets		1
	Other assets		60
	Total	$	1,333
	Liabilities assumed:
Accounts payable	$	72
Accrued expenses		326
Total	$	398
Net Assets Acquired	$	935
Included in the selling, general and administrative expenses for the year ended December 31, 2013 is $0.4 million of expenses related to the VeriTeQ transaction.
The results of VC have been included in the consolidated statement of operations since July 8, 2013, the date of acquisition. Unaudited pro forma results of operations for the years ended December 31, 2013 and 2012 are included below. Such pro forma information assumes that the VC acquisition had occurred as of January 1, 2012. This summary is not necessarily indicative of what our result of operations would have been had VC been a combined entity during such periods, nor does it purport to represent results of operations for any future periods.
(In thousands, except per share amounts)	Year				Year
	Ended				Ended
	December 31,				December 31,
	2013				2012
Net operating revenue	$	18			$	—
Net loss	$	(18,577	)		$	(3,958	)
Net loss per common share – basic and diluted	$	(2.03	)		$	(0.52	)

Note_3_Intangible_Assets

Note 3 - Intangible Assets	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	3. Intangible Assets
	Intangibles and other assets consist of the following:
		December 31,		December 31,		Lives
		2013		2012		(in years)
		(in thousands)		(in thousands)
	Technology, net of accumulated amortization of $627 and $136	$	6,244	$	6,734		14
	Customer relationship, net of accumulated amortization of $141 and $69		359		431		7
	Trademarks, net of accumulated amortization of $35 and $3		415		447		14
		$	7,018	$	7,612
	Estimated amortization of intangible assets for the years ending December 31 is as follows (in thousands):
	2014	$	594
	2015		594
	2016		594
	2017		594
	2018		594
	Thereafter		4,048
		$	7,018
	Amortization of intangibles charged against income amounted to $0.6 million and $0.2 million for the years ended December 31, 2013 and 2012, respectively.
	The estimated fair value of the acquired intangible assets of the acquisitions discussed in Note 2 were determined on the basis of patents and other proprietary rights for technologies, contract lives and estimated revenue, customer relationship and other factors related to forecasted results, including revenue growth rates of 55% - 358% and using discounted cash flow methodology using discount rates ranging from 25% to 45%. Under this method, we estimated the cash flows that each of these intangible assets are expected to generate over the course of their expected economic lives. Actual cash flows may differ significantly from these estimates. The expected economic lives of these intangible assets were determined based upon the expected use of the asset, the ability to extend or renew patents and other contractual provisions associated with the asset, the estimated average life of the associated products, the stability of the industry, expected changes in and replacement value of distribution networks, and other factors deemed appropriate.

Note_4_Accrued_Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Other Liabilities Disclosure [Text Block]	'
	4. Accrued Expenses
	The following table summarizes the significant components of accrued expenses:
		December 31,		December 31,
		2013		2012
		(in thousands)
	Accrued payroll and payroll related	$	1,734	$	709
	Accrued legal		445		291
	Accrued other expenses		539		72
	Total accrued expenses	$	2,718	$	1,072

Note_5_Notes_Payable_and_Restr

Note 5 - Notes Payable and Restricted Cash	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	5. Notes Payable and Restricted Cash
	Financing Transaction
	On November 13, 2013, we entered into the securities purchase agreement (the “Purchase Agreement”) with a group of institutional investors (the “Investors”), relating to the private placement of $1,816,667 in principal amount of senior secured convertible promissory note, or the Notes. The Notes were issued with an original issue discount of $166,667 and the aggregate purchase price of the Notes was $1,650,000. Notwithstanding the purchase price of $1,650,000, $150,000 of the purchase price was be deemed paid at the closing by the cancellation of $150,000 of obligations owed by the Company to the placement agent as more fully discussed below. Therefore, the Notes were issued for a cash purchase price of $1,500,000, and with warrants to purchase up to 2,422,222 shares of our common stock, on the terms set forth below.
	In connection with the financing, we agreed to allow our placement agent to participate in the offering for $150,000 in lieu of our obligation to pay the placement agent a cash fee of $150,000. In addition, the placement agent will receive 5% of the aggregate cash exercise price received by us upon exercise of any Warrants in the offering, and they received 222,222 Warrants entitling them to purchase 222,222 shares of common stock as part of their placement agent fee. Thus, the aggregate number of Warrants issued in the financing was 2,644,444.
	In connection with the sale of the Notes and the Warrants, (i) we entered into a registration rights agreement with the Investors (the "Registration Rights Agreement"), (ii) we and certain of our subsidiaries entered into a security and pledge agreement in favor of the collateral agent for the Investors (the "Security Agreement"), (iii) certain of our subsidiaries entered into a guaranty in favor of the collateral agent for the Buyers (the “Guaranty”), and (iv) we and each depository bank in which such bank account is maintained entered into certain account control agreements with respect to certain accounts described in the Note and the Security Agreement. The transaction closed on November 13, 2013 (the “Closing”).
	Proceeds Received and Restricted Cash
	At Closing, we received proceeds, net of $115,000 of the investors expenses that were paid for by the Company, of $635,000 and approximately $750,000 of the proceeds were placed in restricted bank accounts in amounts proportionate to each investors note balance. The restricted funds will be applied to pay any redemption or other payment due under the applicable note to the applicable holder from time to time. Pursuant to the terms of the financing, a portion of the restricted funds will be released to us upon any conversion of the notes or at any time the balance of the funds placed in the restricted accounts by the note holders exceeds the principal of the applicable note then outstanding. Per the term of the securities purchase agreement, we were required upon the sale of 50,000 shares of MGT Capital Investments Inc.’s common stock that we owned to place the proceeds from the sale into the restricted bank accounts on a pro rata basis. Accordingly, on November 21, 2013, upon the sale of the 50,000 shares of MGT’s common stock under the terms of a stock purchase agreement, we placed approximately $132,500 into the restricted accounts. The balance in the restricted bank accounts totals approximately $0.9 million at December 31, 2013. On April 3, 2014, certain investors transferred approximately $145,000 of the restricted funds to our operating account as more fully discussed in Note 15.
	The Purchase Agreement provides, among other things, that we will (i) not enter into a variable rate transaction at any time while the Notes are outstanding, and (ii) for a period of two years from the date of the Closing, allow the Investors to participate in the purchase of their respective pro rata portion of no less than 50% of the securities offered by us in any future financing transactions.
	Description of the Notes
	The Notes will mature on the first anniversary of the Closing. No interest shall accrue on the Notes unless there is an event of default (as defined in the Notes), in which case interest on the Notes shall commence accruing daily at a rate of eighteen percent (18%) per annum.
	The Notes may be converted into our common stock, at the option of the holder, at any time following issuance, unless the conversion or share issuance under the conversion would cause the holder to beneficially own in excess of 4.99% of our common stock. The Conversion Price of the Notes is $0.75. If and whenever after the Closing we issue or sell, or are deemed to have issued or sold, any shares of common stock for a consideration per share (the “New Issuance Price”) less than a price equal to the Conversion Price in effect immediately prior to such issue or sale or deemed issuance or sale (the foregoing a “Dilutive Issuance”), then, immediately after such Dilutive Issuance, the Conversion Price then in effect shall be reduced to an amount equal to the New Issuance Price. The convertible option of these Notes were bifurcated from the Notes and recorded at its fair value on the date of issuance and at each reporting date, with the change in the fair value being charged/credited to other income/expense.
	The Conversion Price is also subject to adjustment upon the following events:
	●  if we pay a stock dividend or otherwise make a distribution on any class of capital stock that is payable in shares of common stock;
	●  if we subdivide (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of our then outstanding shares of common stock into a larger number of shares; or
	●  if we combine (by combination, reverse stock split or otherwise) one or more classes of our then outstanding shares of common stock into a smaller number of shares.
	In each such case the Conversion Price will be multiplied by the following fraction: (i) the number of shares of common stock outstanding immediately before such event and (ii) the number of shares of common stock outstanding immediately after such event.
	The Notes rank senior to our indebtedness and are secured by a perfected first lien security interest in all of the Company’s and its subsidiaries assets except certain assets of VTQ IP Holding Corporation (IP related to the Company’s dosimeter business) and certain intellectual property assets of PAH (IP related to the Company’s UDI business), which are secured by a second priority lien. The Notes contain certain covenants and restrictions, including, among others, that, for so long as the Notes are outstanding, we will not incur any indebtedness except permitted indebtedness, permit liens on its properties (other than permitted liens under the Notes), make dividends or transfer certain assets.
	If we issue options, convertible securities, warrants or similar securities to holders of our common stock, each holder of a Note has the right to acquire the same as if it had converted its Note into common stock.
	Description of the Warrants
	The Warrants became exercisable at issuance and entitle the Investors to purchase shares of our common stock for a period of five years at an initial exercise price of $2.84 per share. The Exercise Price is subject to adjustment.
	If we are prohibited from issuing shares of our common stock upon exercise of the Warrants due to our failure to have sufficient authorized shares of common stock we will be required to pay cash for the shares we would be required to issue upon exercise of the Warrants at a price per share equal to the greatest closing sale price of the common stock on any trading day commencing on the date the holder provides the exercise notice and ending on the date of payment multiplied by the number of unavailable shares. If the holder of the Warrants purchased shares to deliver upon sale of the shares underlying the Warrants, we will also have to pay any brokerage commissions and other expenses incurred by the holder.
	The Warrants include cashless exercise provisions in the event a registration statement is not effective.
	Lock-Up Agreements
	As a condition to the sale of the securities, the Company's executive officers, management and directors entered into lock-up agreements pursuant to which they agreed not to sell, pledge, hypothecate or otherwise transfer their shares for a period of 12 months commencing on the date of the Closing, subject to certain exceptions for estate planning and similar purposes.
	Notes payable and long-term debt consists of the following (in thousands):
			December 31,			December 31,
			2013			2012
			(in thousands)
	PSID Note for $200 dated January 11, 2012, bears interest at 5% per annum, net of discount of $0 and $43 was originally payable in monthly instalments beginning January 11, 2013 through December 11, 2014. Note was amended in July 2013 to allow for conversion into common stock and extend payment terms. After the note was partially converted into common stock in October 2013, PSID assigned the note to a group of lenders in November 2013. The Company issued 300 warrants to PSID in connection with a letter agreement entered into in November 2013(2)(3)		$	175		$	157
	Convertible term note for $125 issued September 25, 2012 net of discount of $31, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per share and matures on March 31, 2013. Note was issued with warrants to acquire 40 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in March 2013. An additional 40 warrants with an exercise price of $1.57 per share were granted in March 2013 as an inducement to the conversion.(2)			—			94
	Convertible term note for $125 issued October 12, 2012, net of discount of $39, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per shares and matures April 10, 2013. Note was issued with warrants to acquire 40 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in June 2013. An additional 40 warrants with an exercise price of $1.57 per share were granted in June 2013 as an inducement to the conversion.(1)(2)			—			86
	Convertible term note for $100 issued December 31, 2012, net of discount of $55, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per share and matures June 30, 2013. Note was issued with warrants to acquire 29 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in June 2013. An additional 29 warrants with an exercise price of $1.57 per share were granted in June 2013 as an inducement to the conversion.(1) (2)			—			45
	Convertible term note for $50 issued December 31, 2012, net of discount of $28, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per shares and matures June 30, 2013. Note was issued with warrants to acquire 14 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in June 2013. An additional 14 warrants with an exercise price of $1.57 per share were granted in June 2013 as an inducement to the conversion.(1) (2)			—			22
	Demand note for $80 issued October 11, 2013 to CEO, bears interest at 5% per annum, partially repaid in November 2013(1)			30			—
	Demand note for $30 issued October 29, 2013 to CEO, bears interest at 5% per annum(1)			30			—
	Senior Secured Convertible Notes issued November 13, 2013 for $1,817, net of discount of $1,585, to group of institutional investors, are convertible into shares of common stock at $0.75 per share and mature November 13, 2014. Notes were issued with warrants to acquire 2,644 shares of common stock with an exercise price of $2.84 per share.(2)			232			—
	Total notes payable			467			404
	Less: Current maturities			467			326
	Note payable long-term		$	—		$	78
	Subordinated Convertible Note Payable elected at fair value:
	Non-interest bearing subordinated convertible note payable with a principal amount of $3,300 dated December 3, 2012. Note is convertible into common stock equal to 1/3 of the shares beneficially held by the CEO on the date of conversion. Note was amended in July 2013 to extend the maturity date to June 2015. The note was recorded at its fair value and will be revalued at each reporting period with changes in the fair value recorded as other expense/income.		$	4,925		$	2,137
	(1) These notes have been issued to related parties. For additional discussion, see Note 10.
	(2) The warrants are more fully described in Note 7. The fair value of the conversion option is bifurcated and recorded at fair value.
	(3) This note when originally issued was issued to a related party. See Note 10 for additional discussion.
	The scheduled payments due based on maturities of current and long-term debt and at December 31, 2013 are presented in the following table:
	Year:		Amount
			(in thousands)
	2014			1,877	(1)
	2015			3,300
	Total payments		$	5,177
		-1	The PSID Note, which has been assigned to various investors, is only convertible into stock and, thus, is not included in the scheduled payments due in 2014 in the table above.
	Interest expense was approximately $7.1 million for the year ended December 31, 2013. This includes approximately $2.8 million for the initial fair value of the embedded derivative (conversion option) of convertible notes, approximately $3.4 million for the value of warrants issued in connection with debt, including $0.4 million associated with the warrants issued as a placement agent fee, approximately $0.4 million of debt issue costs, which were expensed as incurred, approximately $0.3 million of debt discount accretion and approximately $0.1 million for shares issued to as an inducement to convert notes during 2013.
	Interest expense was $0.1 million during the year ended December 31, 2012 of which approximately $31 thousand related to the accretion of beneficial conversion feature of the convertible notes. We did not incur any interest expense from December 14, 2011 (inception) to December 31, 2011.
	Given the significant amount of non-cash interest expense associated with the conversion option fair value and the value of the warrants issued in connection with debt, the weighted average effective interest rate for the year ended December 31, 2013 is not a meaningful number. The weighted average effective interest rate was 37.62% for the year ended December 31, 2012.

Note_6_Financial_Instruments

Note 6 - Financial Instruments	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Financial Instruments Disclosure [Text Block]	'
	6. Financial Instruments
	Fair Value Measurements
	We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.
	We apply the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Inputs that are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability.
	During the year end December 31, 2013, we had a short-term investment (marketable securities), which we valued using Level 1 inputs. The marketable securities were sold in November 2013. During the year ended December 31, 2013, the subordinated convertible note issued to SNC Holdings Corp., which has a convertible option embedded in the note, the convertible option embedded in the Notes, warrant liabilities and the estimated royalty obligations were valued using Level 3 inputs, and for the year ended December 31, 2012, the note issued to SNC Holdings Corp. and the royalty obligations were valued using Level 3 inputs. The changes in fair value of the subordinated convertible note and the warrant liability during 2013 are reflected in other expense for 2013. There was no change in the estimated fair value of the royalty obligations.
	Notes Payable and Long-Term Debt
	The carrying amount approximates fair value based on management’s estimate of the applied discount rates and fair value adjustments. The subordinated convertible note with an embedded conversion option was discounted at 22.8% at December 31, 2012. Subsequently, we have valued the subordinate convertible note based on the market value of the shares of our common stock into which it is convertible at each period end. We valued the convertible option embedded in the Notes at fair value.
	Warrant Liabilities
	The carrying amounts approximate management’s estimate of the fair value of the warrant liabilities at December 31, 2013 based on the BSM valuation model and using the following assumptions: expected term of 4.87 years, expected volatility of 155%, risk-free interest rates of 1.75%, and expected dividend yield of 0%.
	Estimated Royalty Obligations
	The carrying amount approximates management’s estimate of the fair value of royalty obligations that will be paid (discounted at rates ranging from 25% to 60%) for a period from 3 to 14 years.
	Conversion option of the Notes
	The carrying amount approximates management’s estimate of the fair value of the embedded conversion option at December 31, 2013 based on using a Monte Carlo model with the following assumptions: market price $2.29, term 0.92 years, standard deviation 0.18 and conversion price $0.75.
	The following table summarizes our financial assets and liabilities measured at fair value as presented in the consolidated balance sheets as of December 31, 2013 and December 31, 2012 (in thousands):
		31-Dec-13						31-Dec-12
		Level 1		Level 2		Level 3		Level 1			Level 2		Level 3
	Liabilities:
	Subordinated convertible note with an embedded conversion option	$	—	$	—	$	4,925	$	—		$	—	$	2,137
	Conversion option of the Notes	$	—	$	—	$	3,124	$	—		$	—	$	—
	Warrant liabilities	$	—	$	—	$	6,114	$	—		$	—	$	—
	Royalty obligations	$	—	$	—	$	4,000	$	—		$	—	$	4,000
	The following is a summary of activity of Level 3 liabilities for the year ended December 31, 2013:
		Subordinated		Embedded		Warrant		Estimated
		Note with		Conversion		Liabilities		Royalty
		Convertible		Option of the				Obligations
		Option		Notes
	Balance at December 31, 2012	$	2,137	$	—	$	—	$	4,000
	Initial fair value of conversion option of the Notes		—	2,761			—		—
	Issuances of warrants accounted for as liabilities		—		—		5,394		—
	Change in fair value		2,788	363			720		—
	Balance at December 31, 2013	$	4,925	$	3,124	$	6,114	$	4,000	**
	** Includes $60 thousand of current royalty obligations included in accrued expenses at December 31, 2013.
	The Company’s management considers the carrying values of other current assets and other current liabilities to approximate fair values primarily due to their short-term nature.

Note_7_Stockholders_Deficit

Note 7 - Stockholders' Deficit	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	7. Stockholders’ Deficit
	Preferred Stock
	On June 24, 2013, VAC and its stockholders entered in the Exchange Agreement with VC and on July 8, 2013, the transaction closed. Pursuant to the terms of the Exchange Agreement, VAC exchanged all of its issued and outstanding shares of common stock for 4,107,592 shares of VC’s Series B Preferred Stock. On July 10, 2013, VC realized that it incorrectly issued the Series B Preferred Stock and as result, on July 12, 2013, it exchanged the Series B Preferred Stock for 410,759 shares of its newly created Series C Preferred Stock. The terms of the Series C Preferred Stock are substantially similar to the Series B Preferred Stock, including the aggregate number of shares of common stock into which the Series C Preferred Stock was convertible. Each share of Series C Preferred Stock was converted into twenty shares of VC’s common stock, par value $0.01 per share (the “Conversion Shares”), automatically upon the effectiveness of the Reverse Stock Split on October 18, 2013.
	The Series C Preferred Stock consists of 500,000 authorized shares. The shares of Series C Preferred Stock issued to VAC’s shareholders in connection with the Share Exchange, by their principal terms:
	(a)	converted into a total of 8,215,184 Conversion Shares, constituting approximately 88% of the issued and outstanding shares of common stock of VC, following the “Reverse Stock Split” on October 18, 2013 (as more fully discussed below);
	(b)	have the same voting rights as holders of VC’s common stock on an as-converted basis for any matters that are subject to stockholder vote;
	(c)	are not entitled to any dividends; and
	(d)	are to be treated pari passu with the common stock on liquidation, dissolution or winding up of VC.
	Common Stock
	In July 2013, we issued 41,667 shares of our common stock to an investment advisory firm for services rendered for an aggregate value of $62,500. The shares were valued at the fair market value of the stock on the date of issuance which was $1.50 per share.
	On October 18, 2013, VC filed a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware effecting a one-for-thirty reverse stock split of its common stock (the “Reverse Stock Split”) and a name change to VeriTeQ Corporation. The reverse stock split became effective on October 18, 2013, and every thirty (30) shares of VC's issued and outstanding common stock were automatically converted into one (1) issued and outstanding share of VC's common stock, without any change in the par value per share. The Certificate of Amendment provides that no fractional shares will be issued. Stockholders of record who otherwise would be entitled to receive fractional shares will receive, in lieu thereof, a cash payment based on the volume weighted average price of the Company's common stock as reported on October 21, 2013 on the OTC Markets. All shares and options amounts have been adjusted accordingly for all periods presented in the Annual Report.
	Pursuant to the terms of a July 8, 2013 letter agreement between PSID and the Company, we agreed to issue shares of our common stock as repayment of the PSID Note. Accordingly, in October 2013, we issued approximately 16,666 shares of common stock in connection with a partial repayment of the PSID Note, and we agreed to issue an additional 135,793 shares of our common stock in full repayment of the PSID Note. These share issued by us to PSID in October 2013 were issued in private placement in reliance upon the exemption from the registration requirements set forth in the Act provided for in Section 4(2) of the Securities Act, and Rule 506 of Regulation D promulgated by the SEC thereunder. In connection with the November 13, 2013 financing described in Note 5, PSID assigned the PSID Note to certain investors.
	In October and November 2013, we issued 163,333 shares of common stock to three investor relation firms for services rendered for an aggregate value of approximately $0.4 million. The shares were valued at the fair market value of the stock on the dates of issuance which were $2.70, $2.10 and $2.00.
	At December 31, 2013, VC had authorized 50.0 million shares of common stock of which approximately 9.5 million were issued and outstanding. Of the 9.5 million issued and outstanding shares of common stock at December 31, 2013, 5.7 million were beneficially owned by our Chief Executive Officer.
	Warrants
	We have issued warrants exercisable for shares of common stock for consideration, as follows (in thousands, except exercise price):
	Series/ Issue Date		Warrants			Warrants			Exercised/				Balance				Exercise				Exercisable
			Authorized			Issued			Forfeited				December				Price				Period
													31,								(years)
													2013
	Series A /June 2012			95			95			—				95			$	0.37			3
	Series B / September 2012			40			40			—				40			$	1.57			3
	Series C / October 2012			40			40			—				40			$	1.57			3
	Series D / December 2012			14			14			—				14			$	1.57			5
	Series E /December 2012			29			29			—				29			$	1.57			5
	Series F / March 2013			40			40			—				40			$	1.57			3
	Series G / April 2013			95			95			—				95			$	1.31			3
	Series H / June 2013			83			83			—				83			$	1.57			3
	Series VT a/ November 2013			2,644			2,644			—				2,644			$	2.84			5
	Series VT b/ November 2013			300			300			—				300			$	2.84			5
				3,380			3,380			—				3,380
	The Series A warrants were issued in connection with a stock subscription agreement to an investor. The Series A warrants are exercisable at any time during the exercisable periods. The Series A warrant agreement provides for the number of shares to be adjusted in the event of a stock split, a reverse stock split, a share exchange or other conversion or exchange event in which case the number of warrants and the exercise price of the warrants shall be adjusted on a proportional basis.
	The Series B, C, D, E, F, G and H warrants were issued in connection with promissory notes. The promissory note issued in April 2013 in connection with the series G warrants was repaid during 2013. The promissory notes issued in connection with the series B,C,D, E, F and H warrants are more fully described in Note 5. These warrants are exercisable at any time during the exercisable periods. The warrant agreements provide for the number of shares to be adjusted in the event of a stock split, a reverse stock split, a share exchange or other conversion or exchange event in which case the number of warrants and the exercise price of the warrants shall be adjusted on a proportional basis. The total value of these warrants of approximately $0.3 million was amortized to interest expense over the life of the promissory notes and accordingly, we recorded approximately $0.3 million and $31 thousand of non-cash interest expense related to these warrants during the years ended December 31, 2013 and 2012, respectively.
	The Series VTa warrants were issued on November 13, 2013 in connection with senior secured convertible notes, which are more fully described in Note 5. These warrants are exercisable at any time during the exercisable periods. The warrant agreements provide for the number of shares to be adjusted in the event of a stock split, a reverse stock split, a share exchange or other conversion or exchange event in which case the number of warrants and the exercise price of the warrants shall be adjusted on a proportional basis. In addition, if we issue or sell any shares of our common stock, except certain specified issuances pursuant to the Company’s stock plans or the issuance of common stock pursuant to agreements existing on November 13, 2013, at a price per share, or the New Exercise Price, less than the Exercise Price in effect immediately before the issuance or sale, then immediately after such dilutive issuance, the Exercise Price will be reduced to the New Exercise Price. If there is an adjustment to the Exercise Price as a result of any of the dilution events specified in the Warrant agreements, the number of shares of common stock that may be purchased upon exercise of the Warrant will be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable for the adjusted number of shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment (without regard to any limitations on exercise).
	The Series VTb warrants were issued November 13, 2013 to PSID in connection with a letter agreement between the Company and PSID as more fully discussed in Note 10. The terms of the Series VTb warrants are identical to the Series VTa warrants.
	We determined the value of the warrants issued in 2012 and 2013 on the issuance dates utilizing the following assumptions in the BSM valuation model:
	Warrants Issued		Dividend			Volatility			Expected				Risk-Free				Date of the
			Yield						Lives (Yrs.)				Rate				Assumptions
	Jun-12			0	%		126	%		3				0.34	%		1-Jun-12
	Sep-12			0	%		126	%		3				0.35	%		25-Sep-12
	Oct-12			0	%		126	%		3				0.35	%		12-Oct-12
	Dec-12			0	%		126	%		5				0.72	%		31-Dec-12
	Mar-13			0	%		126	%		3				0.38	%		18-Mar-13
	Apr-13			0	%		126	%		3				0.34	%		10-Apr-13
	Jun-13			0	%		126	%		3				0.52	%		1-Jun-13
	Nov-13			0	%		154	%		5				1.41	%		13-Nov-13
	Stock Option Activity
	In accordance with the Compensation – Stock Compensation Topic of the Codification, awards granted are valued at fair value and compensation cost is recognized on a straight line basis over the service period of each award. Upon exercise of stock options, the Company’s policy is to issue new shares from its authorized but unissued balance of common stock outstanding that have been reserved for issuance under our stock option plans. A summary of the status of our stock options as of December 31, 2013, and changes during the two years then ended, is presented below.
	During 1999, we adopted the 1999 Flexible Stock Plan and the 1999 Employees’ Stock Plan. During 2003, we adopted the 2003 Flexible Stock Plan. The options granted under these plans have contractual terms ranging from six to ten years.
	Under the 1999 Flexible Plan, the number of shares authorized to be issued or sold, or for which options, Stock Appreciation Rights (“SARs”), or Performance Shares may be granted to our officers, directors and employees is approximately 15,000. As of December 31, 2013, approximately 14,000 options have been granted, net of forfeitures, approximately 1,700 options are outstanding, and approximately 1,000 shares are available for future issuance. The options vest as determined by our board of directors and are exercisable over a period of five years.
	The 1999 Employees’ Stock Purchase Plan authorizes the grant of options to employees who purchase shares of common stock. The number of shares authorized to be issued for which options may be granted is approximately 5,400. As of December 31, 2013, approximately 4,200 options have been granted, 1,100 are outstanding and 1,200 shares are available for grant.
	Under the 2003 Flexible Plan, the number of shares authorized to be issued or sold, or for which options, SARs, or performance shares may be granted to our officers, directors and employees is approximately 133,000. As of December 31, 2013, approximately 93,000 options have been granted, net of forfeitures, approximately 29,000 are outstanding and approximately 41,000 shares are available for future issuances. The options vest as determined by our board of directors and are exercisable over a period of three to ten years.
	Under the Digital Angel Transition Stock Option Plan, the number of shares authorized to be issued is approximately 61,000. As of December 31, 2013, approximately 40,000 shares have been granted, net of forfeitures, approximately 30,000 are outstanding, and approximately 21,000 remain available for issuance. The options vest as determined by the board of directors, and are exercisable over a period of three to nine years.
	On July 12, 2013, pursuant to the Exchange Agreement, a majority of our voting stockholders adopted resolutions by written consent approving the DAC 2013 Stock Incentive Plan (the “Plan”), under which employees, including officers and directors, and consultants may receive awards. Awards under the Plan include incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock performance units, performance shares, cash awards and other stock based awards. The purposes of the Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees and consultants, to promote the success of the Company’s business and to link participants’ directly to stockholder interests through increased stock ownership. The Plan became effective on October 18, 2013, upon effectiveness of the Reverse Stock Split. On October 18, 2013, the outstanding stock options under the three VAC’s stock plans were converted into options to acquire VC’s common stock under the DAC 2013 Stock Plan and VAC’s three former stock plans were terminated.
	The aggregate number of shares of the Company’s common stock that may be subject to awards under the Plan, subject to adjustment upon a change in capitalization, is 5,000,000 shares. Such shares of common stock may be authorized, but unissued, or reacquired shares of common stock. Shares of common stock that were subject to Plan awards that expire or become unexercisable without having been exercised in full shall become available for future awards under the Plan. At December 31, 2013, approximately 2.6 million options are outstanding, and approximately $2.4 million options remain available for issuance under this Plan.
	In addition, as of December 31, 2013, we have granted approximately 4,400 options, net of forfeitures, and have outstanding approximately 4,000 options which were granted outside of the above plans as an inducement to employment.
	During the years ended December 31, 2013 and 2012, we granted 1.0 million and 0.5 million options, respectively. The weighted average fair values of the options granted during the years ended December 31, 2013 and 2012 were $1.33 and $0.90, respectively.
	We account for our stock-based compensation plans in accordance with ASC 718-10, Compensation – Stock Compensation. Under the provisions of ASC 718-10, the fair value of each stock option is estimated on the date of grant using a BSM option-pricing formula, and amortizing that value to expense over the expected performance or service periods using the straight-line attribution method. The weighted average values of the assumptions used to value the options granted in the year ended December 31, 2013 were as follows: expected term of 5 years, expected volatility of 126%, risk-free interest rates of 0.83%, and expected dividend yield of 0%. The weighted average values of the assumptions used to value the options granted in the year ended December 31, 2012 were as follows: expected term of 5 years, expected volatility of 126%, risk-free interest rates of 0.67%, and expected dividend yield of 0%. The expected life represents an estimate of the weighted average period of time that options are expected to remain outstanding given consideration to vesting schedules and the Company’s historical exercise patterns. Expected volatility is estimated based on the historical volatility of similar companies’ common stock. The risk free interest rate is estimated based on the U.S. Federal Reserve’s historical data for the maturity of nominal treasury instruments that corresponds to the expected term of the option. The expected dividend yield is 0% based on the fact that we have never paid dividends and have no present intention to pay dividends.
	During the years ended December 31, 2013 and 2012, we recorded $1.4 million and $0.4 million, respectively, in compensation expense related to stock options granted to our directors, employees and consultants (who provide corporate support services).
	A summary of the stock option activity for our stock options plans for 2013 and 2012 is as follows (shares in thousands):
			2013						2012
			Number of			Weighted-			Number of				Weighted-
			Options			Average			Options				Average
			Exercise						Exercise
			Price						Price
Outstanding on January 1			1,531		$	0.31			—			$	—
Granted			1,050			1.57			458				1.05
Assumed in PAH acquisition			—			—			1,307				0.05
Assumed in VC acquisition			75			344.15			—				—
Forfeited or expired			(28	)		151.64			(234	)			0.31
Outstanding at December 31			2,628			9.01			1,531				0.31
Exercisable at December 31(1)			1,579			13.95			1,264				0.05
Vested or expected to vest at December 31(2)			2,628			9.01			1,531				0.31
Shares available on December 31 for options that may be granted			2,503						1,684
-1	The intrinsic value of a stock option is the amount by which the fair value of the underlying stock exceeds the exercise price of the option. The fair value of our common stock was $2.29 at December 31, 2013 based upon the closing price on the OTC Market. As of December 31, 2013, the aggregate intrinsic value of options outstanding, exercisable and vested or expected to vest was $3.8 million, $3.0 million and $3.8 million, respectively.
-2	The weighted average remaining contractual life for exercisable options is 6.27 years, and for options vested or expected to vest, is 5.41 years, as of December 31, 2013.
There were no stock option exercises during the years ended December 31, 2013 and 2012. The total fair value of options vested during the years ended December 31, 2013 and 2012, was approximately $0.4 million and nil, respectively. As of December 31, 2013, there was no unrecognized compensation cost related to unvested share-based compensation arrangements granted under our plans, as all unvested options at December 31, 2013 vested on January 1, 2014.
The following table summarizes information about our stock options at December 31, 2013 (shares in thousands):
											Outstanding Options										Exercisable Stock
																					Options
	Range of Exercise										Shares				Weighted-			Weighted-			Shares		Weighted-
	Prices														Average			Average Exercise					Average Exercise
															Remaining			Price					Price
															Contractual Life
															in Years
		$0			to			$100				2,593				5.5		$	1.03			1,544	$	0.66
		$101			to			$200				5				4.2			156.71			5		156.71
		$201			to			$300				1				3.6			244.8			1		244.8
		$301			to			$400				1				2.6			342.29			1		342.29
		$401			to			$500				—				2.5			451.2			—		451.2
		$501			to			$600				11				1.8			568.39			11		568.39
		$601			to			$700				5				0.2			661.82			5		661.82
		$701			to			$800				1				1.7			733.38			1		733.38
		$801			to			$900				9				1.2			871.2			9		871.2
		$901			to			$1,000				2				0.7			966.93			2		966.93
	Total stock options											2,628				5.4			9.01			1,579		13.95
As of December 31, 2013, 2.5 million shares were available for issuance under our plans.
Restricted Stock Grants
In January 2013, we issued approximately 0.9 million shares of our restricted common stock to a member of our senior management. This restricted stock vests in January 2015. The total value of the restricted stock of approximately $1.4 million is being expensed over the vesting period. During the year ended December 31, 2013, we recorded $0.7 million in compensation expense related to the restricted stock. We did not incur any restricted stock expense in 2012.

Note_8_Income_Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	8. Income Taxes
	The benefit for income taxes consists of:
		Year Ended			Year Ended
		December 31,			December 31,
		2013			2012
	Current income tax benefit	$	—		$	—
	Deferred income taxes benefit					800
	Total income tax benefit	$	---		$	800
	We did not have an income tax (provision) benefit for the year ended December 31, 2013. The income tax benefit of $0.8 million for the year ended December 31, 2012 resulted from the utilization of deferred tax assets to offset a deferred tax liability associated with the PAH acquisition. We have incurred losses and therefore have provided a valuation allowance of approximately $2.9 million against our net deferred tax assets as of December 31, 2013.
	The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities consist of the following:
		2013			2012
	Deferred tax assets:
	Accrued compensation and stock-based compensation	$	1,580		$	401
	Net operating loss carryforwards		1,961			454
	Gross deferred tax assets		3,541			855
	Valuation allowance		(2,905	)		(152	)
	Deferred tax liabilities:
	Amortization of intangible assets		(636	)		(703	)
	Gross deferred tax liabilities		(636	)		(703	)
	Net Deferred Tax Assets	$	—		$	—
	The valuation allowance for deferred tax assets increased by $2.8 million and $0.2 million in 2013 and 2012, respectively due primarily to interest and other expenses not currently deductible and net operating losses.
	At December 31, 2013, we had U.S. net operating loss carryforwards of approximately $5.1 million for income tax purposes, which expire in varying amounts through 2033. The amount of any benefit from our U.S. tax net operating losses is dependent on: (1) our ability to generate future taxable income, and (2) the unexpired amount of net operating loss carryforwards available to offset amounts payable on such taxable income. Any greater than a fifty percent change in ownership under IRC section 382 places significant annual limitations on the use of our U.S. net operating losses to offset any future taxable U.S. income we may generate. As a result of the VeriTeQ acquisition, which was a tax-free reorganization, we exceed the fifty percent threshold, and as a result, effective on July 8, 2013, the closing date of the VeriTeQ transaction, VC’s U.S. net operating losses became limited to approximately $0.5 million in the aggregate. Accordingly, under purchase accounting, we have eliminated all prior loss carryforwards generated by VC in excess of the amount that is not currently limited. In addition there may be limitations on VAC net operating losses under IRC Section 382 due to common stock issued since inception. Certain future transactions could cause a more than fifty percent ownership change in the future, including (a) additional issuances of shares of common stock by us or (b) acquisitions or sales of shares by certain holders of our shares, including persons who have held, currently hold, or accumulate in the future five percent or more of our outstanding stock.
	The reconciliation of the effective tax rate with the statutory federal income tax (benefit) rate is as follows:
		2013			2012
		%			%
	Statutory tax/(benefit) rate		(35	)		(35	)
	State income taxes, net of federal benefits		(4	)		(4	)
	Transaction costs not deductible		1			—
	Interest and other expenses not deductible		23			—
	Change in deferred tax asset valuation allowance		15			6
			(--	)		(33	)
	We did not have an unrecognized tax benefit at December 31, 2013 and 2012. We file income tax returns in the U.S. federal jurisdiction and various states in which we operate. We will file separate federal and state tax returns for VC and VAC for the periods prior to the VeriTeQ Transaction and consolidated tax returns for subsequent periods. We have not yet filed our U.S. federal and certain state tax returns for VC for 2013 and for VAC for 2013 and 2012 and we do not currently have any examinations ongoing. Tax returns for the years 2010 onwards are subject to federal, state or local examinations.

Note_9_Loss_Per_Share

Note 9 - Loss Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	9. Loss Per Share
	A reconciliation of the numerator and denominator of basic and diluted loss per share is provided as follows, in thousands, except per share amounts:
			2013			2012
	Numerator for basic and diluted loss per share:
	Loss from continuing operations		$	(18,201	)	$	(1,605	)
	Denominator for basic and diluted loss per share:
	Basic and diluted weighted-average shares outstanding (1)(2)			8,607			6,529
	Loss per share — basic and diluted
	Total — basic and diluted		$	(2.11	)	$	(0.25	)
		-1	Basic and diluted loss per common share has been computed by dividing the loss by the weighted average number of common shares outstanding.
		-2	The following stock options and warrants and shares issuable upon conversion of convertible notes payable outstanding at December 31, 2013 and 2012 were not included in the computation of dilutive loss per share because the net effect would have been anti-dilutive:
			31-Dec-13			31-Dec-12
			(in thousands)
	Stock options			2,628			1,531
	Warrants			3,380			218
	Shares issuable upon conversion of convertible notes payable			4,709			2,308
				10,717			4,057

Note_10_Related_Party_Transact

Note 10 - Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	10. Related Party Transactions
	Shared Services Agreement with PSID
	We entered into a shared services agreement (“SSA”) with PSID on January 11, 2012, pursuant to which PSID agreed to provide certain services, including administrative, rent, accounting, business development and marketing, to us in exchange for $30,000 per month. The SSA has also included working capital advances from time to time. The term of the SSA commenced on January 23, 2012. The first payment for such services was not payable until we received gross proceeds of a financing of at least $500,000. On June 25, 2012, the level of resources provided under the SSA was reduced and the agreement was amended, pursuant to which all amounts owed to PSID under the SSA as of May 31, 2012 were converted into approximately 2.3 million shares of VAC’s common stock valued at $0.2 million. In addition, effective June 1, 2012, the monthly charge for the shared services under the SSA was reduced from $30,000 to $12,000.
	On August 28, 2012, the SSA was further amended to align with the level of services being provided, pursuant to which, effective September 1, 2012, the monthly charge for the shared services under the SSA was reduced from $12,000 to $5,000. On April 22, 2013, we and PSID entered into a non-binding letter agreement in which PSID agreed to provide up to an additional $60,000 of support during April and May 2013.
	On July 8, 2013, we entered into a letter Agreement with PSID (the “July Letter Agreement”) to amend certain terms of several agreements between PSID and us. The July Letter Agreement amended certain terms of the SSA entered into between PSID and us on January 11, 2012, as amended, the APA entered into on August 28, 2012, as amended, and the PSID Note dated January 11, 2012, in favor of PSID in the principal amount of $200,000. VC assumed the obligations under the PSID Note in connection with the Share Exchange as of the date of the July Letter Agreement.
	On November 8, 2013, we entered into a Letter Agreement (the “November Letter Agreement”) with PSID which further amended the terms of the several agreements between PSID and us.
	The July Letter Agreement, as modified by the November Letter Agreement, provides for:
		(i)	At closing of a capital raise with cumulative gross proceeds of at least $3.0 million, $100,000 of the balance owed under the SSA shall be due within two business day after funding. Within thirty and sixty days after the initial $100,000 payment, we shall pay $50,000 each (total of an additional $100,000) and the balance of the outstanding amount shall be paid by 90 days after the initial $100,000 is paid. In the event any of the balance is unpaid at March 31, 2014, interest on the outstanding balance accrues at 10% per annum.  If the initial $100,000 payment is made by March 31, 2014, no interest shall accrue so long as we comply with the payment schedule required.
		(ii)	The elimination of minimum royalties payable to PSID under the APA in their entirety. In the event that royalty payments under the APA based on our attainment of certain sales levels are not at least $800,000 for the calendar year 2014, then we shall grant PSID Corporation a non-exclusive, perpetual, non-transferrable, world-wide, fully paid license to said patents.
		(iii)	An amendment to the PSID Note, with a principal and interest balance of $228,000 on September 30, 2013, to provide that no interest will accrue on the PSID Note from July 8, 2013 to September 30, 2013 and to include a conversion feature under which the PSID Note may be repaid, at our option, in VC’s common stock in lieu of cash.
		(iv)	VC will grant PSID a warrant to purchase 300,000 shares of common stock at an exercise price of $2.84. The warrants will be exercisable for a period of five years. The terms and form of warrant will be the same as those granted to the Investors, which are more fully discussed in Note 5.
	Pursuant to the terms of the July Letter Agreement, on October 10, 2013, we issued approximately 16,666 shares of common stock to PSID in partial repayment of the PSID Note, and we agreed to issue an additional 135,793 shares of common stock. In connection with the November 2013 financing as more fully discussed in Note 5, the PSID note was assigned to certain investors.
	As of December 31, 2013 and December 31, 2012, we owed PSID $0.2 million and $0.1 million, respectively under the SSA.
	Accrued Expenses
	Included in accrued expenses at December 31, 2013 and 2012 are approximately $1.6 million and $0.7 million, respectively, owed to the Company's officers and directors.
	Investment from VeriTeQ Corporation’s Director
	Following VC’s approval of the Share Exchange in June 2013, VAC approached VC for a small, short-term bridge loan or equity investment. In light of the many conditions to closing, VC’s board decided not to make the loan or investment. VC’s then interim chief executive officer and president and then chairman of VC’s board, Daniel E. Penni, agreed to make a $25,000 equity investment in VAC. As a result of such investment in June 2013, Mr. Penni owned shares of VAC’s common stock, which have been exchanged for 19,084 shares of VC’s common stock. Mr. Penni continues to serve as a member of VC’s board.
	Notes Payable
	During the years ended December 31, 2013 and 2012, we issued notes payable to certain directors, officers and a relative of a director. These notes are further discussed in Note 5. Subsequent to December 31, 2013, we issued notes payable to certain directors and officers. These notes are further discussed in Note 15.

Note_11_Commitments_and_Contin

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	11. Commitments and Contingencies
	Rentals of space, a vehicle, and office equipment amounted to approximately $77 thousand and $11 thousand for the years ended December 31, 2013 and 2012, respectively. We did not incur rent expense from December 14, 2011 (inception) to December 31, 2011. We lease our headquarter office facility under a lease expiring in May 2018.
	We have entered into employment agreements with Mr. Scott Silverman, our Chief Executive Officer, and Mr. Randolph Geissler, our President. Previously, Messrs. Silverman and Geissler had employment agreements with VAC.
	Scott R. Silverman Employment Agreements
	Effective January 1, 2012, Mr. Scott R. Silverman entered into the Employment and Non-Compete Agreement, or the 2012 Employment Agreement, with VAC. The 2012 Employment Agreement terminated five years from the effective date. The 2012 Employment Agreement provided for an annual base salary in 2012 of $300,000 with minimum annual increases of 10% of the base salary and an annual bonus equal to the annual base salary then in effect. Mr. Silverman was also entitled to an annual non-allocable expense payment of $45,000 each year and other fringe benefits. If Mr. Silverman’s employment was terminated prior to the expiration of the term of the 2012 Employment Agreement, Mr. Silverman was to receive (i) all earned but unpaid salary and bonuses; (ii) the greater of the base salary from the date of termination through December 31, 2016 or two times the base salary; and (iii) the average bonus paid by us to Mr. Silverman for the last three full calendar years (or such lesser time period if the 2012 Employment Agreement was terminated less than three years from the effective date), plus certain fringe benefits required to be paid by us. In addition, the 2012 Employment Agreement contained a change of control provision that provided for the payment of five times the then current base salary and five times the average bonus paid to Mr. Silverman for the three full calendar years immediately prior to the change of control, as defined in the 2012 Employment Agreement. Any outstanding stock options and restricted stock held by Mr. Silverman as of the date of his termination or a change of control became vested and exercisable as of such date, and remained exercisable during the remaining life of the option.
	Mr. Silverman’s 2012 Employment Agreement was terminated effective July 8, 2013 at which time Mr. Silverman entered into a new employment agreement effective with the closing of Exchange Agreement, which was amended and restated on November 14, 2013, (the “Silverman Employment Agreement”) appointing Mr. Silverman as our chairman and chief executive officer, effective as of July 8, 2013 until December 31, 2016. Under the Silverman Employment Agreement, Mr. Silverman will receive a base salary of $330,000, which base salary will be reviewed annually and is subject to a minimum increase of 5% per annum during each calendar year of the term. Accordingly, Mr. Silverman’s salary was increased to $346,500 beginning January 1, 2014. During the term, Mr. Silverman will be eligible to receive an annual bonus, based on performance metrics and goals as determined annually by the Board of Directors, with the amount of such bonus to be determined based upon the annual objectives determined by the compensation committee of the Board of Directors, but in no event to be less than 100% of earned base salary for the applicable year. The bonus shall be paid in cash or, if Mr. Silverman and the Company agree at the time, using shares of the Company’s common stock, at a valuation equal to fair market value. Mr. Silverman is also entitled to (i) an annual non-allocable expense payment of $30,000 payable in two equal instalments on or before April 1st and October 1st of each year; (ii) the Company shall, at its option, either lease for Mr. Silverman an automobile, or reimburse Mr. Silverman for the lease or financing payments incurred by Mr. Silverman on his automobile, the amount of such reimbursement to be reasonably comparable to the current cost of Mr. Silverman’s current automobile. The Company shall reimburse car-related expenses; (iii) the Company shall, at its option, either provide to Mr. Silverman disability insurance that provides standard disability coverage and terms, in an amount of at least equal to $22,500 per month until age 65, or reimburse Mr. Silverman for the premium payments incurred by him for disability insurance coverage for himself, the amount of such reimbursement to be reasonably comparable to the current cost of his disability insurance; (iv) the Company shall provide comprehensive health insurance as it provides to other executives and employees as well as reimbursement of health benefits of up to $5,000 per year; (v) reimbursement for expenses related to business attire in an amount not to exceed $950 per month; and (vi) if the Company elects to secure a key man life insurance policy on the life of Mr. Silverman, it will provide a split-dollar policy. On January 30, 2014, the compensation committee of the board of directors authorized a discretionary bonus in the amount of $100,000 to be paid to Mr. Silverman. This discretionary bonus is in addition to Mr. Silverman’s minimum bonus for 2013 under the terms of his employment agreement. The discretionary bonus shall be accrued. It will be paid in cash after the compensation committee determines we have adequate working capital to make such payments, or, if we are permitted to do so without triggering a reset provision on any outstanding warrants and the applicable employee so elects, in shares of our common stock, in which case the amount of the bonus would be increased by 25%.
	Under the Silverman Employment Agreement, VC agreed to satisfy certain unpaid contractual obligations under Mr. Silverman’s December 2012 Employment Agreement aggregating $912,116, or the Silverman Contractual Obligations, if VC receives gross proceeds of an aggregate of $3,000,000 in cash in any capital investment or capital raise or series of capital investments or capital raises. The Silverman Contractual Obligations shall be payable as follows: (i) one-third (1/3rd) in cash and (ii) two-thirds (2/3rds) in shares of restricted VC common stock, based on the closing price of a share of VC’s common stock on the closing date of the investment. During 2013, Mr. Silverman was paid approximately $66 thousand of the Silverman Contractual Obligations in cash.
	If Mr. Silverman’s employment is terminated prior to the expiration of the term, certain payments become due. In the event Mr. Silverman is terminated with cause or he terminates for any reason other than good reason, Mr. Silverman is entitled to receive (i) earned or accrued but unpaid, base salary, through the date of termination, (ii) any bonus earned or accrued and vested, but unpaid, (iii) the economic value of the employee’s accrued, but unused, vacation time, and (iv) any unreimbursed business expenses incurred by the employee (collectively, the “Accrued Obligations”). In the event Mr. Silverman is terminated without cause or he terminates for good reason, or upon his death, Mr. Silverman is entitled to receive the Accrued Obligations and a termination payment equal to his base salary from the date of termination through December 31, 2016, (or two years whichever is longer) plus bonus for such period, with such bonus being determined based upon the time remaining between the date of termination and December 31, 2016 (or two years, whichever is longer) and with the rate of bonus to be based upon the average annual bonus paid by the Company to Mr. Silverman over the last three (3) full calendar years (or if the Agreement is terminated before Mr. Silverman has been employed by the Company for three (3) full calendar years, for purposes of calculating the average Annual Bonus, the Company will use 100% of Mr. Silverman’s base salary as the annual bonus) plus certain benefits as set forth in the Silverman Employment Agreement.
	In addition, the Silverman Employment Agreement contains a change of control provision that provides for the payment of 299% of Mr. Silverman’s base salary plus 299% of the average annual bonus paid over the last three (3) full calendar years (or 60% of base salary if the Silverman Employment Agreement is terminated before Mr. Silverman has been employed for three full years). Any outstanding stock options and unvested restricted stock held by Mr. Silverman as of the date of termination (other than for cause or by Mr. Silverman without good reason) or a change of control shall become vested and exercisable as of such date, and remain exercisable during the life of the option. In the event Mr. Silverman is terminated for cause or terminates without good reason, any unvested options and restricted stock awards shall terminate and all vested options shall remain exercisable for a period of ninety (90) days. The Silverman Employment Agreement also contains non-compete and confidentiality provisions which are effective from the date of employment through eighteen months from the date the Silverman Employment Agreement is terminated.
	Randolph Geissler Employment Agreements
	On January 2, 2013, VAC entered into an employment agreement with our president, Mr. Randolph Geissler with an effective date of September 1, 2012, or the Geissler 2012 Agreement. The Geissler 2012 Agreement called for an annual base salary of $200,000 and discretionary annual and incentive bonuses. The term of the Geissler 2012 Agreement was two years from the effective date and could be extended by mutual consent of the parties. The Geissler 2012 Agreement also provided for the issuance on January 2, 2013 of 4.5 million restricted shares of our common stock, which vested the earlier of January 2, 2015 or a change of control of VAC. Payments of compensation under the Geissler 2012 Agreement commenced within 30 days of VAC receiving a capital investment from any third party in excess of $5.0 million, the first payment of which was to be retroactive to September 1, 2012 and included any and all sums due and owing to Mr. Geissler at that time. Upon termination of the Geissler 2012 Agreement by Mr. Geissler or us, Mr. Geissler was entitled to receive any earned but unpaid salary and bonuses and all outstanding stock options and restricted stock was to be forfeited. Upon termination of the agreement by us without cause, Mr. Geissler was also entitled to receive certain fringe benefits through December 2014. Upon a change of control as defined in the agreement, Mr. Geissler was entitled to receive any earned but unpaid salary and bonuses and any outstanding stock options and restricted stock was to vest and the stock options were to remain exercisable through the life of the option. The Geissler 2012 Agreement was terminated effective July 8, 2013 at which time Mr. Geissler entered into a new employment agreement effective with the closing of Exchange Agreement, which was amended and restated on November 14, 2013, or the Geissler Employment Agreement appointing Mr. Geissler as president of VC, effective as of July 8, 2013. The Geissler Employment Agreement is for a term of two (2) years and is renewable for additional one (1) year periods upon mutual agreement. Under the Geissler Employment Agreement, Mr. Geissler will receive a base salary of $200,000, which base salary will be reviewed annually and is subject to a minimum increase of 5% per annum each calendar year. Accordingly, Mr. Geissler’s salary was increased to $210,000 beginning January 1, 2014. Mr. Geissler is eligible to receive an annual bonus, based on performance metrics and goals as determined annually by the Board of Directors, with the amount of such bonus to be determined based upon the annual objectives determined by the compensation committee of the Board of Directors, but in no event to be less than 100% of earned base salary for the applicable year. The bonus shall be paid in cash or, if Mr. Geissler and the Company agree at the time, using shares of the Company’s common stock, at a valuation equal to fair market value. On January 30, 2014, the compensation committee of the board of directors authorized a discretionary bonus in the amount of $75,000 to be paid to Mr. Geissler. This discretionary bonus is in addition to Mr. Geissler’s minimum bonus for 2013 under the terms of his employment agreement. The discretionary bonus shall be accrued. It will be paid in cash after the compensation committee determines we have adequate working capital to make such payments, or, if we are permitted to do so without triggering a reset provision on any outstanding warrants and the applicable employee so elects, in shares of our common stock, in which case the amount of the bonus would be increased by 25%.
	Mr. Geissler is also entitled to the following: (i) the Company shall, at its option, either lease for Mr. Geissler an automobile, or reimburse Mr. Geissler for the lease or financing payments incurred by Mr. Geissler’s on his automobile, the amount of such reimbursement to be reasonably comparable to 75% of the current cost on the automobile then being provided to the Company’s CEO. The Company shall reimburse car-related expenses; (ii) the Company shall, at its option, either provide to Mr. Geissler disability insurance that provides standard disability coverage and terms, in an amount of at least equal to $15,000 per month until age 65, or reimburse Mr. Geissler for the premium payments incurred by him for disability insurance coverage for himself, the amount of such reimbursement to be reasonably comparable to the current cost of his disability insurance; (iii) the Company shall provide comprehensive health insurance as it provides to other executives and employees; (iv) reimbursement for expenses related to business attire in an amount not to exceed $950 per month; and (v) if the Company elects to secure a key man life insurance policy on the life of Mr. Geissler, it will provide a split-dollar policy.
	Under the Geissler Employment Agreement, the Company agreed to satisfy certain currently unpaid contractual obligations under Mr. Geissler’s January 2, 2013 employment agreement of $166,666, or the Geissler Contractual Obligations, if VC receives gross proceeds of an aggregate of $3,000,000 in cash in any capital investment or capital raise or series of capital investments or capital raises. The Geissler Contractual Obligations shall be payable as follows: (i) one-third (1/3rd) in cash and (ii) two-thirds (2/3rds) in shares of restricted VC common stock, based on the closing price of a share of VC’s common stock on the closing date of the investment.
	If Mr. Geissler’s employment is terminated for cause or he terminates for any reason other than good reason, Mr. Geissler is entitled to receive the Accrued Obligations. In the event Mr. Geissler is terminated without cause or he terminates for good reason, or termination upon his death, Mr. Geissler is entitled to receive the Accrued Obligations and a termination payment equal to one times his base salary plus the previous year’s bonus, but no less than one times his base salary. In the event that Mr. Geissler is terminated as a result of a change in control, Mr. Geissler is entitled to receive the Accrued Obligations and a termination payment equal to two times his base salary, plus the previous year’s bonus, but no less than two times his base salary. Any termination payment shall be payable to Mr. Geissler in cash, or if Mr. Geissler agrees, in shares of the Company’s common stock valued at market value. Any outstanding stock options and unvested restricted stock held by Mr. Geissler as of the date of termination (other than for cause or by Mr. Geissler without good reason) or a change of control shall become vested and exercisable as of such date, and remain exercisable during the life of the option. In the event Mr. Geissler is terminated for cause or terminates without good reason, any unvested options and restricted stock awards shall terminate and all vested options shall remain exercisable for a period of ninety (90) days. The Geissler Employment Agreement also contains non-compete and confidentiality provisions which are effective from the date of employment through one year from the date the Geissler Employment Agreement is terminated.
	The approximate minimum payments required under operating leases and employment contracts that have initial or remaining terms in excess of one year at December 31, 2013, are as follows (in thousands):
	Year	Minimum		Employment
		Rental		Contracts
		Payments
	2014	$	48	$	1,229
	2015		47		1,285
	2016		40		1,343
	2017		42		—
	2018		17		—
		$	194	$	3,857
	Michael Krawitz Employment Agreement
	In addition, effective January 31, 2014, we entered into an employment agreement with Michael Krawitz to serve as our Chief legal and Financial Officer. Mr. Krawitz’ employment agreement is described in Note 15.
	Liquidation of Signature Industries, Limited
	In March 2013, VC appointed a liquidator and initiated the formal liquidation of a U.K. subsidiary, Signature Industries Limited (“Signature”), primarily related to its outstanding liabilities. VC used £40,000 ($61,000) of the purchase price from the sale of Signature’s former division, Digital Angel Radio Communications Limited (“DARC”) to satisfy its estimated portion of Signature’s outstanding liabilities. However, one party has submitted a claim to the liquidator for approximately £244,000 (U.S. $0.4 million). This claim is associated with an outsourced manufacturing agreement related to a terminated manufacturing contract. As a result of the termination of the contract, Signature did not purchase any product under the manufacturing agreement and, accordingly, VC, in consultation with outside legal counsel, does not believe that any amount is owed per the terms of the agreement. However, this claim could result in VC having to pay an additional estimated portion of Signature’s outstanding liabilities. We expect the liquidation to be completed by the middle of 2014, although it could extend beyond the expected timeframe.

Note_12_Legal_Proceedings

Note 12 - Legal Proceedings	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Legal Matters and Contingencies [Text Block]	'
	12. Legal Proceedings
	We have been informed by the New Jersey Department of Environmental Protection that a subsidiary of a predecessor business, sold a building in 2006 for which an environmental action has been claimed. The claim is being reviewed by the Company’s outside legal counsel. We have not yet determined the impact on our financial condition or cash flows, if any.

Note_13_Supplemental_Cash_Flow

Note 13 - Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'
Cash Flow, Supplemental Disclosures [Text Block]	'
	13. Supplemental Cash Flow Information
	We had the following non-cash operating, investing and financing activities (in thousands):
		For the Year		For the Year
		Ended		Ended
		December 31,		December 31,
		2013		2012
	Non-cash operating activities:
	Issuance of shares of common stock to settle the partial payment of payable under a shared services agreement with PSID	$	—	$	160
	Non-cash investing and financing activities:
	Net assets acquired from VC in excess of cash acquired for common stock		117		—
	Acquisition of assets for common stock, assumption of stock options and a promissory note		—	$	1,200
	Notes and accrued interest related to notes converted into common stock		420		—
	Issuance of common stock in partial payment of notes payable		25		—

Note_14_Restatement_and_Amendm

Note 14 - Restatement and Amendment of Previously Reported Financial Statements	12 Months Ended
	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
	14. Restatement and Amendment of Previously Reported Financial Statements
	In connection with the preparation of the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2014, the Company identified an error relating to the accounting for the financing transaction described below.
	On November 13, 2013, the Company entered into a financing transaction, as more fully discussed in Note 5, which included the notes in the principal amount of $1,816,667. The notes are convertible into shares of the Company’s common stock at an initial exercise price of $0.75 per share. The notes provided for the initial conversion price to be reset to lower amounts in the event the Company issues its common stock or is deemed to have issued its common stock at a price below the conversion price in effect at that time. This provision results in what is referred to as an embedded derivative and should have been bifurcated and a liability recorded for the embedded derivative at fair value upon the issuance of the Notes and at December 31, 2013 in the Original Report. This oversight resulted in an understatement of the derivative liability of $3.1 million at December 31, 2013. Accordingly, we are restating our previously filed financial statements to reflect the fair value of this embedded derivative liability as a current liability on our Consolidated Balance Sheet at December 31, 2013 and to reflect the initial fair value and change in the fair value through December 31, 2013 in our Consolidated Statement of Operations, Consolidated Statement of Comprehensive Losses, Consolidated Statement of Changes in Stockholders’ Deficit and Consolidated Statement of Cash Flows for the year ended December 31, 2013 and from December 14, 2011 (our inception date) to December 31, 2013. We are also restating certain unaudited pro forma results related to a business combination in Note 3 for the year ended December 31, 2013. The correction of the error did not impact any assets.
	The effect of the restatement on each of our financial statements at and as of December 31, 2013 and for the period from December 14, 2011 (Inception) to December 31, 2013 as well as certain unaudited pro forma information for the year ended December 31, 2013 is as follows:
	Consolidated Balance Sheets Data
	(in thousands, except par value)
		As
		Previously
		Reported						As Restated
		31-Dec-13				Correction		31-Dec-13
	LIABILITIES AND STOCKHOLDERS’ DEFICIT
	Liabilities for conversion option under convertible notes	$	—		$	3,124		$	3,124
	Total current liabilities	$	4,250		$	3,124		$	7,374
	Total liabilities	$	19,229		$	3,124		$	22,353
	Accumulated deficit during the development stage	$	(16,700	)	$	(3,124	)	$	(19,824	)
	Total stockholders’ deficit	$	(11,010	)	$	(3,124	)	$	(14,134	)
	Consolidated Statements of Operations Data
	(in thousands, except per share data)
		For the Year			Correction			For the Year
		Ended						Ended
		December 31,						December 31,
		2013 As Previously Reported						2013 As Restated
	Other expense	$	4,164		$	363		$	4,527
	Interest expense	$	4,335		$	2,761		$	7,096
	Loss before income taxes	$	(15,077	)	$	(3,124	)	$	(18,201	)
	Net loss	$	(15,077	)	$	(3,124	)	$	(18,201	)
	Net loss per common share — basic and diluted	$	(1.75	)	$	(0.36	)	$	(2.11	)
		For the Period			Correction			For the Period
		from						from December 14,
		December 14,						2011
		2011						(Inception) to
		(Inception) to						December 31,
		December 31,						2013
		2013						As Restated
		As Previously
		Reported
	Other expense	$	4,164		$	363		$	4,527
	Interest expense	$	4,468		$	2,761		$	7,229
	Loss before income taxes	$	(17,500	)	$	(3,124	)	$	(20,624	)
	Net loss	$	(16,700	)	$	(3,124	)	$	(19,824	)
	Consolidated Statements of Comprehensive Loss Data
	(in thousands)
		For the Year			Correction			For the Year
		Ended						Ended
		December 31,						December 31,
		2013 As						2013 As
		Previously						Restated
		Reported
	Net loss	$	(15,077	)	$	(3,124	)	$	(18,201	)
	Comprehensive loss	$	(15,077	)	$	(3,124	)	$	(18,201	)
		For the Period				Correction				For the Period
		from								from
		14-Dec								December 14,
		2011								2011
		(Inception) to								(Inception) to
		December 31,								31-Dec-13
		2013								As Restated
		As
		Previously
		Reported
	Net loss	$	(16,700	)		$	(3,124	)		$	(19,824	)
	Comprehensive loss	$	(16,700	)		$	(3,124	)		$	(19,824	)
	Consolidated Statement of Changes in Stockholders’ Deficit Data
(in thousands)
	For the Year				Correction				For the Year
	Ended								Ended
	December 31,								December 31,
	2013  As								2013 As
	Previously								Restated
	Reported
Net loss for the year ended December 31, 2013	$	(15,077	)		$	(3,124	)		$	(18,201	)
Accumulated deficit at December 31, 2013	$	(16,700	)		$	(3,124	)		$	(19,824	)
Total stockholders’ deficit at December 31, 2013	$	(11,010	)		$	(3,124	)		$	(14,134	)
Consolidated Statements of Cash Flows Data
(in thousands)
	For the Year				Correction				For the Year
	Ended								Ended
	December 31,								December 31,
	2013 As								2013 As
	Previously								Restated
	Reported
Cash flows from operating activities:
Net loss	$	(15,077	)		$	(3,124	)		$	(18,201	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	$	3,873			$	2,761			$	6,634
Change in fair value of conversion option under convertible notes	$	—			$	363			$	363
	For the Period				Correction				For the Period
	from December								from
	14, 2011								December 14,
	(Inception) to								2011
	December 31,								(Inception) to
	2013 As								December 31,
	Previously								2013 As
	Reported								Restated
Cash flows from operating activities:
Net loss	$	(16,700	)		$	(3,124	)		$	(19,824	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	$	3,991			$	2,761			$	6,752
Change in fair value of conversion option under convertible notes	$	—			$	363			$	363
Pro Forma Information
Unaudited pro forma results of operations for the year ended December 31, 2013 as originally reported and as restated is presented below. Such pro forma is more fully explained in Note 3.
(In thousands, except per share amounts)	For the Year				Correction				For the Year
	Ended								Ended
	December 31,								December 31,
	2013 As								2013 As
	Previously								Restated
	Reported
Net loss	$	(15,453	)		$	(3,124	)		$	(18,577	)
Net loss per common share – basic and diluted	$	(1.69	)		$	(0.34	)		$	(2.03	)

Note_15_Subsequent_Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	15. Subsequent Events
	Michael E. Krawitz Employment Agreement
	Effective January 31 2014, we entered into an employment agreement with Michael Krawitz to serve as our Chief Legal and Financial Officer, or the Krawitz Employment Agreement. The Krawitz Employment Agreement is for an initial term of two (2) years and is renewable for additional one (1) year terms upon mutual agreement of the parties. Under the Krawitz Employment Agreement, Mr. Krawitz will receive a base salary of $210,000, which base salary will be reviewed annually by the compensation committee and is subject to a minimum increase of 5% per annum, with the first increase to be effective on January 1, 2015. Mr. Krawitz is also entitled to (i) disability insurance or reimbursement of disability insurance in an amount at least equal to $15,000 per month until age 65; (ii) health insurance; (iii) an automobile or reimbursement of lease or financing payments incurred, the amount of such reimbursement to be reasonably comparable to 75% of the current cost of the automobile being provided to our Chief Executive Officer; and (iv) life insurance. During the term of the Krawitz Employment Agreement, Mr. Krawitz is eligible to receive an annual bonus based on performance metrics and goals as determined annually by the Company’s Board of Directors, with the amount of such bonus to be determined based upon annual objectives determined by the compensation committee of the Board of Directors, but in no event will be less than 100% of Mr. Krawitz’s earned base salary for the applicable year.
	If Mr. Krawitz’s employment is terminated prior to the expiration of the term, certain payments become due. In the event Mr. Krawitz is terminated with cause or he terminates for any reason other than good reason, Mr. Krawitz is entitled to receive (i) earned or accrued but unpaid, base salary, through the date of termination, (ii) any bonus earned or accrued and vested, but unpaid, (iii) the economic value of the employee’s accrued, but unused, vacation time, and (iv) any unreimbursed business expenses incurred by the employee, collectively, the Krawitz Accrued Obligations. In the event Mr. Krawitz is terminated without cause or he terminates for good reason, Mr. Krawitz is entitled to receive the Krawitz Accrued Obligations and a termination payment equal to his base salary plus the previous year’s bonus (but no less than one times his base salary). In the event that Mr. Krawitz is terminated as a result of a change in control, Mr. Krawitz is entitled to receive any Krawitz Accrued Obligations and a termination payment equal to two times his base salary, plus the previous year’s bonus, but no less than two times his base salary. Any outstanding stock options and unvested restricted stock held by Mr. Krawitz as of the date of termination (other than for cause or by Mr. Krawitz without good reason) or a change of control shall become vested and exercisable as of such date, and remain exercisable during the life of the option. In the event Mr. Krawitz is terminated for cause or terminates without good reason, any unvested options and restricted stock awards shall terminate and all vested options shall remain exercisable for a period of ninety (90) days. The Krawitz Employment Agreement also contains non-compete provisions which are effective from the date of employment through one year from the date the Krawitz Employment Agreement is terminated.
	Letter Agreement with Digital Angel Radio Communications Limited. (DARC)
	On January 30, 2014, we and the buyers of DARC entered into a letter agreement under which we agreed to accept a payment of £62,000 (USD approximately $0.1 million) in full and final settlement of a deferred purchase price related to VC’s sale of DARC in March 2013. As a result, we will record, a loss of approximately USD $52,000 in the first quarter of 2014. All of the other provisions (including, without limitation, the indemnities) agreed between VC, and/or the Buyers under the stock purchase agreement and any related documents remain in full force and effect.
	Promissory Notes Entered Into Subsequent to December 31, 2013
	We have entered into the following promissory notes subsequent to December 31, 2013. Several of these notes are with our directors and officers as noted:
		●	On January 8, 2014, the Company entered into a promissory note, with our then director and current director and Chief Legal and Financial Officer, Michael Krawitz, wherein Mr. Krawitz loaned the Company the principal amount of $60,000. The note bears interest at 5% per annum and is due on demand.
		●	On January 15, 2014, the Company entered into a promissory note with our President, Randolph Geissler, wherein Mr. Geissler loaned the Company the principal amount of $40,000. The note bears interest at 5% per annum and is due on demand.
		●	On January 15, 2014, the Company entered into a promissory note with our Chairman of the Board and CEO, Scott Silverman, wherein Mr. Silverman loaned the Company the principal amount of $60,000. The note bears interest at 5% per annum and is due on demand. On April 7, 2014, $8,500 of the note was repaid leaving a current balance of $51,500 outstanding.
		●	On February 4, 2014, the Company entered into a promissory note with Corbin Properties LLC, wherein Corbin Properties loaned to the Company the principal amount of $175,000. The note matures on February 4, 2015, bears interest at the rate of 10% per annum and can be prepaid without penalty.
		●	On March 4, 2014, the Company entered into a promissory note with our director, Daniel Penni, wherein Mr. Penni loaned the Company the principal amount of $25,000. The note bears interest at 5% per annum and is due on demand.
		●	On March 5, 2014, the Company entered into a promissory note with Deephaven Enterprises, Inc. wherein Deephaven Enterprises, Inc. loaned the Company the principal amount of $25,000. The note bears interest at 9% per annum and matures on March 5, 2015. At any such time as would not cause a change to, or a right to change, the economics of any outstanding warrants or other debt, the note shall be automatically amended to allow the holder to convert the note, or any part thereof, into validly issued, fully paid and non-assessable shares of common stock of the Company. The number of shares of common stock issuable upon conversion of any conversion amount shall be determined by dividing (x) such conversion amount by (y) the conversion price. Conversion amount means the sum of (x) portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made and (y) all accrued and unpaid interest with respect to such portion of the principal amount. Conversion price means, as of any conversion date or other date of determination, $0.35, adjusted for any stock splits, reverse stock splits or similar transactions.
		●	On March 6, 2014, the Company entered into a promissory note with James Rybicki Trust where James Rybicki Trust loaned the Company the principal amount of $25,000. The note bears interest at 9% per annum and matures on March 6, 2015. At any such time as would not cause a change to, or a right to change, the economics of any outstanding warrants or other debt, the note shall be automatically amended to allow the holder to convert the note, or any part thereof, into validly issued, fully paid and non-assessable shares of common stock of the Company. The number of shares of common stock issuable upon conversion of any conversion amount shall be determined by dividing (x) such conversion amount by (y) the conversion price. Conversion amount means the sum of (x) portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made and (y) all accrued and unpaid interest with respect to such portion of the principal amount. Conversion price means, as of any conversion date or other date of determination, $0.35, adjusted for any stock splits, reverse stock splits or similar transactions.
		●	On March 10, 2014, the Company entered into a promissory note with the CEO of PSID, William Caragol, wherein Mr. Caragol loaned the Company the principal amount of $25,000. The note matures on March 10, 2015, bears interest at the rate of 9% per annum and can be prepaid without penalty. At any such time as would not cause a change to, or a right to change, the economics of any outstanding Warrants or Other Debt (as defined in the note) of the Company, the note shall be automatically amended to allow the holder to convert the note, or any part thereof, into validly issued, fully paid and non-assessable shares of common stock of the Company in accordance with the following provisions: (i)  the number of shares of common stock issuable upon conversion of any Conversion Amount shall be determined by dividing (x) such Conversion Amount by (y) the Conversion Price (the “Conversion Rate”). “Conversion Amount” means the sum of (x) portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made and (y) all accrued and unpaid interest with respect to such portion of the principal amount. “Conversion Price” means, as of any Conversion Date or other date of determination, 60% of the lowest closing bid price over the ten trading days immediately preceding the date of the delivery or deemed delivery of the applicable Conversion Notice. All such determinations to be appropriately adjusted for any share dividend, share split, share combination, reclassification or similar transaction that proportionately decreases or increases the common stock during such 10-day calculation period.
		●	On March 20, 2014, the Company entered into a promissory note with Deephaven Enterprises, Inc. wherein Deephaven Enterprises, Inc. loaned the Company the principal amount of $61,225. The note matures on March 20, 2015, bears interest at the rate of 9% per annum and can be prepaid without penalty. At any such time as would not cause a change to, or a right to change, the economics of any outstanding Warrants or Other Debt (as defined in the note), certain warrants held by the Deephaven Enterprises, Inc. or its owner: (i) would be amended to change the exercise price thereof to $.35 per shares; (ii) would allow the holder to tender the note at any time in lieu of payment of the exercise price on any warrants held by the holder or owner; and (iii) the Company will issue a new warrant to acquire 300,000 shares of the Company’s common stock at a price of $.35 per share. Notwithstanding anything in the note to the contrary, these are not valid or binding, and shall not be deemed to be a part of this note, so long as their existence would trigger a reduction in the exercise price or other change in the terms of any warrant issued by the Company to any person, other than to an officer or director (a “Warrant”), or would trigger a default or the change in the conversion or other economic terms under any indebtedness or securities or related agreements of the Company (“Other Debt”), or would give the holder of any such Warrant or Other Debt the right to alternative pricing or economics as a result of the existence of the terms contained in this section. The provisions of this section are intended and shall be interpreted as to comply with and neither contravene nor trigger the provisions of section 2 of the Warrants issued on November 13, 2013 and Section 7 of the Notes issued November 13, 2013.
	Release of a Portion of Restricted Funds
	During the first week of April, 2014, to provide the Company with additional liquidity, certain of the investors released approximately $145,000 of the funds that were previously held in restricted bank accounts pursuant to the terms of the November 13, 2013 financing, which is more fully discussed in Note 5. Therefore, the balance in the restricted accounts aggregates approximately $0.7 million as of April 15, 2014.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	The accompanying financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We are in the development stage, have incurred operating losses since our inception and have a working capital deficit. Failure to raise capital to fund our operations and generate positive cash flow to fund such operations will have a material adverse effect on our financial condition. These factors raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from this uncertainty.
	We need to raise additional funds to fund our operations till we begin to ship our products and we may not be able to obtain debt or equity funding at all or if available, they may not be on favorable terms.
	Although we had negative working capital at December 31, 2013, we are hopeful that we will be able to generate enough cash from capital raises, business operations as we begin to ship our products, additional issuances of promissory notes to related parties and others and through other investing and financing sources as well as from our ability to delay certain salary and bonus payments to senior management until funds are available and to undertake other cash management initiatives, including working with our vendors to continue to allow us to extend payment terms in order to operate our business for the twelve months ending December 31, 2014. In November 2013, we entered into a $1,816,667 convertible debt financing as more fully described in Note 5, which matures on November 13, 2014. Under the terms of the financing, $750,000 of the proceeds were required to be placed in restricted bank accounts. In addition, $132,500 of proceeds from the sale of marketable securities that we sold under the terms of a securities purchase agreement with one of the investors was required to be placed in the restricted accounts. Thus, the restricted funds totaled $0.9 million at December 31, 2013. Per the terms of the financing, the restricted funds were to be applied to pay any redemption or other payments due under the applicable note to the applicable holder from time to time with a portion of the restricted funds to be released to us upon any conversion of the notes or at any time the balance of the funds placed in the restricted accounts by the note holders exceeds the principal of the applicable note then outstanding. However, to provide the Company with additional liquidity, on April 3, 2014, certain investors allowed the transfer of approximately $145,000 of the restricted funds to our operating account.
	Our goal is to achieve profitability and to generate positive cash flows from operations. Our capital requirements depend on a variety of factors, including but not limited to, the cash that will be required to grow our business operations and to service our debt. Failure to have the funds held in the restrictive bank accounts released to us, to raise additional capital to fund our operations and to generate positive cash flow from such operations will have a material adverse effect on our financial condition, results of operations and cash flows.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The financial statements include our accounts and the accounts of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America (“U.S.”) requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on the knowledge of current events and actions we may undertake in the future, they may ultimately differ from actual results. Included in these estimates are assumptions used in determining the lives of long-lived assets, in Black-Scholes-Merton (“BSM”) valuation models in estimating the fair value of stock-based compensation, promissory notes with an embedded convertible options and royalty obligations and in determining valuation allowances for intangible assets, deferred tax assets, among others.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	We maintained our domestic cash in two financial institutions during the year ended December 31, 2013. Balances were insured up to Federal Deposit Insurance Corporation limits of $250,000 per institution. At times, cash balances may exceed the federally insured limits.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventory consisted of purchased finished goods at December 31, 2013. We did not have inventory on hand at December 31, 2012. Inventory is valued at the lower of the value using the first-in, first-out (“FIFO)” cost method, or market
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment, consisting primarily of computer equipment, and are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful life of the related assets (generally three years for computer equipment and 10 years for other equipment). Depreciation expense for the years ended December 31, 2013 and 2012 was approximately $1,000 and nil, respectively.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible Assets
	We account for intangible assets in accordance with the Intangibles — Goodwill and Other Topic of the Codification. Intangible assets deemed to have an indefinite life, such as goodwill, are reviewed at least annually for impairment. Intangible assets with finite lives are amortized over their estimated useful lives. We do not have any intangible assets with indefinite lives.
	We have intangible assets consisting of technology, customer relationship and trademarks, which are more fully discussed in Note 2 and 3. These intangible assets are amortized over their expected economic lives ranging from 7 to 14 years. The lives were determined based upon the expected use of the asset, the ability to extend or renew patents, trademarks and other contractual provisions associated with the asset, the stability of the industry, expected changes in and replacement value of distribution networks and other factors deemed appropriate. We continually evaluate whether events or circumstances have occurred that indicate the remaining estimated useful lives of our definite-lived intangible assets warrant revision or that the remaining balance of such assets may not be recoverable. We use an estimate of the related undiscounted cash flows over the remaining life of the asset in measuring whether the asset is recoverable. We believe that no impairment of our intangible assets existed as of December 31, 2013.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	At December 31, 2013, we had five stock-based employee compensation plans which are described more fully in Note 7. In accordance with the Compensation – Stock Compensation Topic of the Codification, awards granted are valued at fair value and compensation cost is recognized on a straight line basis over the service period of each award.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	We recognize of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of timing differences such as amortization of intangible assets, deferred officers' compensation and stock-based compensation. A valuation allowance is provided against net deferred tax assets where we determine realization is not currently judged to be more likely than not. We recognize and measure uncertain tax positions through a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. We consider many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes. Accordingly, we report a liability for unrecognized tax benefits resulting from the uncertain tax positions taken or expected to be taken in a tax return and recognize interest and penalties, if any, related to uncertain tax positions in income tax expense.
Earnings Per Share, Policy [Policy Text Block]	'
	Loss Per Common Share and Common Share Equivalent
	Basic and diluted loss per common share has been computed by dividing the loss by the weighted average number of common shares outstanding. Since we have incurred losses attributable to common stockholders, diluted loss per common share has not been computed by giving effect to all potentially dilutive common shares that were outstanding during the period. Dilutive common shares consist of incremental shares issuable upon exercise of stock options, warrants and convertible notes payable to the extent that the average fair value of our common stock for each period is greater than the exercise/conversion price of the derivative securities.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Impact of Recently Issued Accounting Standards
	From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies will issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC” or “Codification”) are communicated through issuance of an Accounting Standards Update (“ASU”).
	In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, an amendment to FASB ASC Topic 220. The update requires disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This ASU was effective prospectively for our fiscal years, and interim periods within those years beginning after December 15, 2012. The adoption of this did not have a material impact on our financial statements.
	In July 2013, ASU ("2013-11"), Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists - a consensus of the FASB Emerging Issues Task Force, was issued to eliminate diversity in practice. ASU 2013-11 requires that companies net their unrecognized tax benefits against all same-jurisdiction net operating losses or tax credit carryforwards that would be used to settle the position with a tax authority. This new guidance is effective prospectively for annual reporting periods beginning on or after December 15, 2013 and interim periods therein. The adoption of ASU 2013-11 will not have a material effect on our consolidated financial statements because it aligns with our historical presentation.

Note_2_Acquisitions_Tables

Note 2 - Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Note 2 - Acquisitions (Tables) [Line Items]	'
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'
	Acquisition	Dates		Acquisition			Intangible		Description of Assets
		Acquired		Price			Assets
							Acquired
	(in thousands)
	PositiveID Animal Health Corporation	1/11/12		$	1,200		$	2,000	Implantable RFID medical device technologies
	Bio Sensor patents from PSID	8/28/12			—			—	Assignment of bio sensor patents
	Asset Purchase Agreement from SNC Holding Corp.	12/3/12		$	5,820		$	5,820	Radiation dose monitoring technology for healthcare industry
	VeriTeQ Corporation	7/8/13		$	935		$	—	Cash, marketable securities and receivables, among others
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Intangible Assets:
	Technology	$	1,500
	Customer relationship		500
	Deferred tax liability		(800	)
	Net	$	1,200
	4.0 million shares of common stock issued and assumption of PAH options	$	760
	Estimated royalty obligations		300
	Promissory note, net		140
		$	1,200
Business Acquisition, Pro Forma Information [Table Text Block]	'
	(In thousands, except per share amounts)	Year				Year
		Ended				Ended
		December 31,				December 31,
		2013				2012
	Net operating revenue	$	18			$	—
	Net loss	$	(18,577	)		$	(3,958	)
	Net loss per common share – basic and diluted	$	(2.03	)		$	(0.52	)
VC Acquisition [Member]	'
Note 2 - Acquisitions (Tables) [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Value of VC’s common stock outstanding on July 8, 2013 (1,029 shares @ $.90 per share)	$	926
	Value of VC’s stock options outstanding on July 8, 2013		9
	Total	$	935
	Assets purchased:
	Cash	$	818
	Marketable securities		239
	Current portion of other receivable		168
	Prepaid and other assets		47
	Fixed assets		1
	Other assets		60
	Total	$	1,333
	Liabilities assumed:
	Accounts payable	$	72
	Accrued expenses		326
	Total	$	398
	Net Assets Acquired	$	935
Purchase Commitment [Member]	'
Note 2 - Acquisitions (Tables) [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Intangible Assets:
	Technology	$	5,370
	Trademarks		450
	Total	$	5,820
	Estimated royalty obligations	$	3,700
	Note at fair value		2,100
	Assumption of liabilities		20
	Total	$	5,820

Note_3_Intangible_Assets_Table

Note 3 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
		December 31,		December 31,		Lives
		2013		2012		(in years)
		(in thousands)		(in thousands)
	Technology, net of accumulated amortization of $627 and $136	$	6,244	$	6,734		14
	Customer relationship, net of accumulated amortization of $141 and $69		359		431		7
	Trademarks, net of accumulated amortization of $35 and $3		415		447		14
		$	7,018	$	7,612
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	2014	$	594
	2015		594
	2016		594
	2017		594
	2018		594
	Thereafter		4,048
		$	7,018

Note_4_Accrued_Expenses_Tables

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		December 31,		December 31,
		2013		2012
		(in thousands)
	Accrued payroll and payroll related	$	1,734	$	709
	Accrued legal		445		291
	Accrued other expenses		539		72
	Total accrued expenses	$	2,718	$	1,072

Note_5_Notes_Payable_and_Restr1

Note 5 - Notes Payable and Restricted Cash (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		December 31,			December 31,
		2013			2012
		(in thousands)
	PSID Note for $200 dated January 11, 2012, bears interest at 5% per annum, net of discount of $0 and $43 was originally payable in monthly instalments beginning January 11, 2013 through December 11, 2014. Note was amended in July 2013 to allow for conversion into common stock and extend payment terms. After the note was partially converted into common stock in October 2013, PSID assigned the note to a group of lenders in November 2013. The Company issued 300 warrants to PSID in connection with a letter agreement entered into in November 2013(2)(3)	$	175		$	157
	Convertible term note for $125 issued September 25, 2012 net of discount of $31, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per share and matures on March 31, 2013. Note was issued with warrants to acquire 40 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in March 2013. An additional 40 warrants with an exercise price of $1.57 per share were granted in March 2013 as an inducement to the conversion.(2)		—			94
	Convertible term note for $125 issued October 12, 2012, net of discount of $39, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per shares and matures April 10, 2013. Note was issued with warrants to acquire 40 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in June 2013. An additional 40 warrants with an exercise price of $1.57 per share were granted in June 2013 as an inducement to the conversion.(1)(2)		—			86
	Convertible term note for $100 issued December 31, 2012, net of discount of $55, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per share and matures June 30, 2013. Note was issued with warrants to acquire 29 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in June 2013. An additional 29 warrants with an exercise price of $1.57 per share were granted in June 2013 as an inducement to the conversion.(1) (2)		—			45
	Convertible term note for $50 issued December 31, 2012, net of discount of $28, bears interest at 10% per annum, is convertible into shares of common stock at $1.57 per shares and matures June 30, 2013. Note was issued with warrants to acquire 14 shares of common stock with an exercise price of $1.57 per share. Note was converted into common stock in June 2013. An additional 14 warrants with an exercise price of $1.57 per share were granted in June 2013 as an inducement to the conversion.(1) (2)		—			22
	Demand note for $80 issued October 11, 2013 to CEO, bears interest at 5% per annum, partially repaid in November 2013(1)		30			—
	Demand note for $30 issued October 29, 2013 to CEO, bears interest at 5% per annum(1)		30			—
	Senior Secured Convertible Notes issued November 13, 2013 for $1,817, net of discount of $1,585, to group of institutional investors, are convertible into shares of common stock at $0.75 per share and mature November 13, 2014. Notes were issued with warrants to acquire 2,644 shares of common stock with an exercise price of $2.84 per share.(2)		232			—
	Total notes payable		467			404
	Less: Current maturities		467			326
	Note payable long-term	$	—		$	78
	Subordinated Convertible Note Payable elected at fair value:
	Non-interest bearing subordinated convertible note payable with a principal amount of $3,300 dated December 3, 2012. Note is convertible into common stock equal to 1/3 of the shares beneficially held by the CEO on the date of conversion. Note was amended in July 2013 to extend the maturity date to June 2015. The note was recorded at its fair value and will be revalued at each reporting period with changes in the fair value recorded as other expense/income.	$	4,925		$	2,137
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Year:	Amount
		(in thousands)
	2014		1,877	(1)
	2015		3,300
	Total payments	$	5,177

Note_6_Financial_Instruments_T

Note 6 - Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
		31-Dec-13						31-Dec-12
		Level 1		Level 2		Level 3		Level 1			Level 2		Level 3
	Liabilities:
	Subordinated convertible note with an embedded conversion option	$	—	$	—	$	4,925	$	—		$	—	$	2,137
	Conversion option of the Notes	$	—	$	—	$	3,124	$	—		$	—	$	—
	Warrant liabilities	$	—	$	—	$	6,114	$	—		$	—	$	—
	Royalty obligations	$	—	$	—	$	4,000	$	—		$	—	$	4,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
		Subordinated		Embedded		Warrant		Estimated
		Note with		Conversion		Liabilities		Royalty
		Convertible		Option of the				Obligations
		Option		Notes
	Balance at December 31, 2012	$	2,137	$	—	$	—	$	4,000
	Initial fair value of conversion option of the Notes		—	2,761			—		—
	Issuances of warrants accounted for as liabilities		—		—		5,394		—
	Change in fair value		2,788	363			720		—
	Balance at December 31, 2013	$	4,925	$	3,124	$	6,114	$	4,000	**

Note_7_Stockholders_Deficit_Ta

Note 7 - Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	Series/ Issue Date		Warrants			Warrants			Exercised/				Balance				Exercise				Exercisable
			Authorized			Issued			Forfeited				December				Price				Period
													31,								(years)
													2013
	Series A /June 2012			95			95			—				95			$	0.37			3
	Series B / September 2012			40			40			—				40			$	1.57			3
	Series C / October 2012			40			40			—				40			$	1.57			3
	Series D / December 2012			14			14			—				14			$	1.57			5
	Series E /December 2012			29			29			—				29			$	1.57			5
	Series F / March 2013			40			40			—				40			$	1.57			3
	Series G / April 2013			95			95			—				95			$	1.31			3
	Series H / June 2013			83			83			—				83			$	1.57			3
	Series VT a/ November 2013			2,644			2,644			—				2,644			$	2.84			5
	Series VT b/ November 2013			300			300			—				300			$	2.84			5
				3,380			3,380			—				3,380
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	'
	Warrants Issued		Dividend			Volatility			Expected				Risk-Free				Date of the
			Yield						Lives (Yrs.)				Rate				Assumptions
	Jun-12			0	%		126	%		3				0.34	%		1-Jun-12
	Sep-12			0	%		126	%		3				0.35	%		25-Sep-12
	Oct-12			0	%		126	%		3				0.35	%		12-Oct-12
	Dec-12			0	%		126	%		5				0.72	%		31-Dec-12
	Mar-13			0	%		126	%		3				0.38	%		18-Mar-13
	Apr-13			0	%		126	%		3				0.34	%		10-Apr-13
	Jun-13			0	%		126	%		3				0.52	%		1-Jun-13
	Nov-13			0	%		154	%		5				1.41	%		13-Nov-13
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			2013						2012
			Number of			Weighted-			Number of				Weighted-
			Options			Average			Options				Average
						Exercise							Exercise
						Price							Price
	Outstanding on January 1			1,531		$	0.31			—			$	—
	Granted			1,050			1.57			458				1.05
	Assumed in PAH acquisition			—			—			1,307				0.05
	Assumed in VC acquisition			75			344.15			—				—
	Forfeited or expired			(28	)		151.64			(234	)			0.31
	Outstanding at December 31			2,628			9.01			1,531				0.31
	Exercisable at December 31(1)			1,579			13.95			1,264				0.05
	Vested or expected to vest at December 31(2)			2,628			9.01			1,531				0.31
	Shares available on December 31 for options that may be granted			2,503						1,684
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
												Outstanding Options										Exercisable Stock
																						Options
		Range of Exercise										Shares				Weighted-			Weighted-			Shares		Weighted-
		Prices														Average			Average Exercise					Average Exercise
																Remaining			Price					Price
																Contractual Life
																in Years
			$0			to			$100				2,593				5.5		$	1.03			1,544	$	0.66
			$101			to			$200				5				4.2			156.71			5		156.71
			$201			to			$300				1				3.6			244.8			1		244.8
			$301			to			$400				1				2.6			342.29			1		342.29
			$401			to			$500				—				2.5			451.2			—		451.2
			$501			to			$600				11				1.8			568.39			11		568.39
			$601			to			$700				5				0.2			661.82			5		661.82
			$701			to			$800				1				1.7			733.38			1		733.38
			$801			to			$900				9				1.2			871.2			9		871.2
			$901			to			$1,000				2				0.7			966.93			2		966.93
		Total stock options											2,628				5.4			9.01			1,579		13.95

Note_8_Income_Taxes_Tables

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		Year Ended			Year Ended
		December 31,			December 31,
		2013			2012
	Current income tax benefit	$	—		$	—
	Deferred income taxes benefit					800
	Total income tax benefit	$	---		$	800
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		2013			2012
	Deferred tax assets:
	Accrued compensation and stock-based compensation	$	1,580		$	401
	Net operating loss carryforwards		1,961			454
	Gross deferred tax assets		3,541			855
	Valuation allowance		(2,905	)		(152	)
	Deferred tax liabilities:
	Amortization of intangible assets		(636	)		(703	)
	Gross deferred tax liabilities		(636	)		(703	)
	Net Deferred Tax Assets	$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		2013			2012
		%			%
	Statutory tax/(benefit) rate		(35	)		(35	)
	State income taxes, net of federal benefits		(4	)		(4	)
	Transaction costs not deductible		1			—
	Interest and other expenses not deductible		23			—
	Change in deferred tax asset valuation allowance		15			6
			(--	)		(33	)

Note_9_Loss_Per_Share_Tables

Note 9 - Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		2013			2012
	Numerator for basic and diluted loss per share:
	Loss from continuing operations	$	(18,201	)	$	(1,605	)
	Denominator for basic and diluted loss per share:
	Basic and diluted weighted-average shares outstanding (1)(2)		8,607			6,529
	Loss per share — basic and diluted
	Total — basic and diluted	$	(2.11	)	$	(0.25	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		31-Dec-13			31-Dec-12
		(in thousands)
	Stock options		2,628			1,531
	Warrants		3,380			218
	Shares issuable upon conversion of convertible notes payable		4,709			2,308
			10,717			4,057

Note_11_Commitments_and_Contin1

Note 11 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	'
	Year	Minimum		Employment
		Rental		Contracts
		Payments
	2014	$	48	$	1,229
	2015		47		1,285
	2016		40		1,343
	2017		42		—
	2018		17		—
		$	194	$	3,857

Note_13_Supplemental_Cash_Flow1

Note 13 - Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'
		For the Year		For the Year
		Ended		Ended
		December 31,		December 31,
		2013		2012
	Non-cash operating activities:
	Issuance of shares of common stock to settle the partial payment of payable under a shared services agreement with PSID	$	—	$	160
	Non-cash investing and financing activities:
	Net assets acquired from VC in excess of cash acquired for common stock		117		—
	Acquisition of assets for common stock, assumption of stock options and a promissory note		—	$	1,200
	Notes and accrued interest related to notes converted into common stock		420		—
	Issuance of common stock in partial payment of notes payable		25		—

Note_14_Restatement_and_Amendm1

Note 14 - Restatement and Amendment of Previously Reported Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]	'
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	'
		As
		Previously
		Reported						As Restated
		31-Dec-13				Correction		31-Dec-13
	LIABILITIES AND STOCKHOLDERS’ DEFICIT
	Liabilities for conversion option under convertible notes	$	—		$	3,124		$	3,124
	Total current liabilities	$	4,250		$	3,124		$	7,374
	Total liabilities	$	19,229		$	3,124		$	22,353
	Accumulated deficit during the development stage	$	(16,700	)	$	(3,124	)	$	(19,824	)
	Total stockholders’ deficit	$	(11,010	)	$	(3,124	)	$	(14,134	)
		For the Year			Correction			For the Year
		Ended						Ended
		December 31,						December 31,
		2013 As Previously Reported						2013 As Restated
	Other expense	$	4,164		$	363		$	4,527
	Interest expense	$	4,335		$	2,761		$	7,096
	Loss before income taxes	$	(15,077	)	$	(3,124	)	$	(18,201	)
	Net loss	$	(15,077	)	$	(3,124	)	$	(18,201	)
	Net loss per common share — basic and diluted	$	(1.75	)	$	(0.36	)	$	(2.11	)
		For the Period			Correction			For the Period
		from						from December 14,
		December 14,						2011
		2011						(Inception) to
		(Inception) to						December 31,
		December 31,						2013
		2013						As Restated
		As Previously
		Reported
	Other expense	$	4,164		$	363		$	4,527
	Interest expense	$	4,468		$	2,761		$	7,229
	Loss before income taxes	$	(17,500	)	$	(3,124	)	$	(20,624	)
	Net loss	$	(16,700	)	$	(3,124	)	$	(19,824	)
		For the Year			Correction			For the Year
		Ended						Ended
		December 31,						December 31,
		2013 As						2013 As
		Previously						Restated
		Reported
	Net loss	$	(15,077	)	$	(3,124	)	$	(18,201	)
	Comprehensive loss	$	(15,077	)	$	(3,124	)	$	(18,201	)
		For the Period				Correction				For the Period
		from								from
		14-Dec								December 14,
		2011								2011
		(Inception) to								(Inception) to
		December 31,								31-Dec-13
		2013								As Restated
		As
		Previously
		Reported
	Net loss	$	(16,700	)		$	(3,124	)		$	(19,824	)
	Comprehensive loss	$	(16,700	)		$	(3,124	)		$	(19,824	)
		For the Year				Correction				For the Year
		Ended								Ended
		December 31,								December 31,
		2013  As								2013 As
		Previously								Restated
		Reported
	Net loss for the year ended December 31, 2013	$	(15,077	)		$	(3,124	)		$	(18,201	)
	Accumulated deficit at December 31, 2013	$	(16,700	)		$	(3,124	)		$	(19,824	)
	Total stockholders’ deficit at December 31, 2013	$	(11,010	)		$	(3,124	)		$	(14,134	)
		For the Year				Correction				For the Year
		Ended								Ended
December 31,		December 31,
2013 As		2013 As
Previously		Restated
Reported
Cash flows from operating activities:
Net loss	$	(15,077	)		$	(3,124	)		$	(18,201	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	$	3,873			$	2,761			$	6,634
Change in fair value of conversion option under convertible notes	$	—			$	363			$	363
	For the Period				Correction				For the Period
	from December								from
	14, 2011								December 14,
	(Inception) to								2011
	December 31,								(Inception) to
	2013 As								December 31,
	Previously								2013 As
	Reported								Restated
Cash flows from operating activities:
Net loss	$	(16,700	)		$	(3,124	)		$	(19,824	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	$	3,991			$	2,761			$	6,752
Change in fair value of conversion option under convertible notes	$	—			$	363			$	363
(In thousands, except per share amounts)	For the Year				Correction				For the Year
	Ended								Ended
	December 31,								December 31,
	2013 As								2013 As
	Previously								Restated
	Reported
Net loss	$	(15,453	)		$	(3,124	)		$	(18,577	)
Net loss per common share – basic and diluted	$	(1.69	)		$	(0.34	)		$	(2.03	)

Note_1_Organization_and_Summar1

Note 1 - Organization and Summary of Significant Accounting Policies (Details) (USD $)

1 Months Ended

0 Months Ended

12 Months Ended

25 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

Oct. 18, 2013

Jul. 12, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 30, 2013

Dec. 31, 2012

Jul. 08, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 17, 2013

Sep. 30, 2013

Jul. 12, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 12, 2013

Jul. 12, 2013

Apr. 03, 2014

Apr. 07, 2014

Apr. 03, 2014

Oct. 18, 2013

Jul. 12, 2013

Nov. 30, 2013

Nov. 13, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 13, 2013

Nov. 30, 2013

Nov. 21, 2013

Nov. 30, 2013

Series B Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Computer Equipment [Member]

Non Computer Equipment [Member]

Series B Preferred Stock Converted to Series C Convertible Preferred Stock [Member]

Series C Preferred Stock Convertible Into Twenty Shares of VC's Common Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

VC Acquisition [Member]

Investors [Member]

Investors [Member]

Minimum [Member]

Maximum [Member]

Proceeds from Financing [Member]

Proceeds from Financing [Member]

Proceeds from Sale of Marketable Securities [Member]

Proceeds from Sale of Marketable Securities [Member]

Issued and Outstanding Common Stock Exchanged for Series B Convertible Preferred Stock [Member]

Subsequent Event [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,816,667

$1,816,667

'

'

'

'

'

'

Increase in Restricted Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

750,000

132,500

132,500

Restricted Cash and Cash Equivalents

'

'

900,000

900,000

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Restricted Cash

'

'

882,000

882,000

'

'

'

'

'

'

'

'

'

'

'

'

145,000

-145,000

-145,000

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Converted (in Shares)

'

'

'

'

'

'

4,107,592

8,215,184

8,215,184

'

'

'

'

'

'

'

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

Preferred Stock, Conversion Basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'410,759

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

'

'

$10

$10

'

$10

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$0.01

$0.01

$0.01

$0.01

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Percentage of Ownership after Transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

91.00%

'

'

'

'

'

'

'

'

Exchange Ratio

'

0.19083

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized (in Shares)

'

'

5,000,000

5,000,000

'

5,000,000

'

'

'

500,000

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Issued (in Shares)

'

'

0

0

'

0

'

'

'

410,759

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issued Outstanding Shares Following Reverse Merger Percentage

88.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity Note, Stock Split, Conversion Ratio

30

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding (in Shares)

9,302,674

'

9,459,000

9,459,000

'

7,021,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized (in Shares)

'

'

50,000,000

50,000,000

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Income (Loss) Attributable to Parent

'

'

'

17,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Financial Institutions

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash, FDIC Insured Amount

'

'

250,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciation

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'14 years

'

'

'

'

Note_2_Acquisitions_Details

Note 2 - Acquisitions (Details) (USD $)

Dec. 31, 2013

Nov. 05, 2013

Oct. 10, 2013

Oct. 05, 2013

Jul. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jan. 11, 2012

Jul. 31, 2013

Jul. 08, 2013

Jan. 11, 2012

Oct. 18, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 08, 2013

Jan. 11, 2012

Jan. 11, 2012

Dec. 31, 2012

Dec. 31, 2013

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2013

Selling, General and Administrative Expenses [Member]

VAC Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Notes Payable, Other Payables [Member]

Subsequent Event [Member]

Intellectual Property [Member]

Convertible Subordinated Debt [Member]

Equity Option [Member]

Equity Option [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

Purchase Agreement SNC Holding Corp [Member]

Purchase Agreement SNC Holding Corp [Member]

Maximum [Member]

VeriTeQ Corporation [Member]

VeriTeQ Corporation [Member]

PositiveID Animal Health Corporation [Member]

Purchase Agreement SNC Holding Corp [Member]

Purchase Agreement SNC Holding Corp [Member]

Note 2 - Acquisitions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

Business Acquisition, Equity Interest Issued or Issuable, Value Assigned

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$300,000

'

'

'

'

'

Business Combination Consideration Transferred Acquiree Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

Stock Options Assumed in Business Acquisition (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,900,000

1,307,000

'

'

'

'

Conversion of Stock, Shares Converted (in Shares)

'

'

'

'

'

'

'

6,900,000

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

200,000

'

'

3,300,000

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

'

'

'

'

'

Fair Value Inputs, Discount Rate

'

'

'

'

'

'

'

'

'

'

11.90%

'

'

'

'

'

'

'

'

'

'

'

Investment Options, Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.05

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 219 days

'8 years 73 days

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

106.60%

126.00%

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.62%

1.50%

'

'

'

'

'

'

Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

Payments for Royalties

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

Accrued Royalties

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

License Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

20,000

'

Future Minimum Sub-license Payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200,000

'

Convertible Debt, Fair Value Disclosures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

'

Royalty Guarantees, Commitments, Amount

3,940,000

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,700,000

'

Payments for Purchase of Other Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,800,000

'

Finite-Lived Intangible Assets, Gross

'

'

'

'

'

'

'

'

'

'

'

'

5,400,000

'

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

$2.29

$2

$2.10

$2.70

$1.50

'

'

'

$0.90

$0.90

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Acquisition Related Costs

'

'

'

'

'

'

$400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_2_Acquisitions_Details_Ac

Note 2 - Acquisitions (Details) - Acquisitions (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
PositiveID Animal Health Corporation [Member]	'
Business Acquisition [Line Items]	'
Date Acquired	11-Jan-12
Acquisition Price	$1,200
Intangible Assets Acquired	2,000
VeriTeQ Corporation [Member]	'
Business Acquisition [Line Items]	'
Date Acquired	8-Jul-13
Acquisition Price	935
Bio Sensor Patents [Member]	'
Business Acquisition [Line Items]	'
Date Acquired	28-Aug-12
Purchase Agreement SNC Holding Corp [Member]	'
Business Acquisition [Line Items]	'
Date Acquired	3-Dec-12
Acquisition Price	5,820
Intangible Assets Acquired	$5,820

Note_2_Acquisitions_Details_PA

Note 2 - Acquisitions (Details) - PAH Acquisition (USD $)	12 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Technology-Based Intangible Assets [Member]	Customer Relationships [Member]	Deferred Tax Liability [Member]	PositiveID Animal Health Corporation [Member]
			PositiveID Animal Health Corporation [Member]	PositiveID Animal Health Corporation [Member]	PositiveID Animal Health Corporation [Member]
Note 2 - Acquisitions (Details) - PAH Acquisition [Line Items]	'	'	'	'	'	'
Intangible Assets	'	'	$1,500	$500	($800)	$1,200
4.0 million shares of common stock issued and assumption of PAH options	760	'	'	'	'	760
Estimated royalty obligations	'	60	'	'	'	300
Promissory note, net	404	467	'	'	'	140
	'	'	'	'	'	$1,200

Note_2_Acquisitions_Details_PA1

Note 2 - Acquisitions (Details) - PAH Acquisition (Parentheticals) (PositiveID Animal Health Corporation [Member])	12 Months Ended
	Dec. 31, 2013
PositiveID Animal Health Corporation [Member]	'
Note 2 - Acquisitions (Details) - PAH Acquisition (Parentheticals) [Line Items]	'
Common stock, shares issued	4,000,000

Note_2_Acquisitions_Details_SN

Note 2 - Acquisitions (Details) - SNC Holding Purchase Agreement (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Feb. 28, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Technology-Based Intangible Assets [Member]	Trademarks [Member]	Purchase Agreement SNC Holding Corp [Member]	Purchase Agreement SNC Holding Corp [Member]
			Purchase Agreement SNC Holding Corp [Member]	Purchase Agreement SNC Holding Corp [Member]
Note 2 - Acquisitions (Details) - SNC Holding Purchase Agreement [Line Items]	'	'	'	'	'	'
Intangible Assets	'	'	$5,370	$450	'	$5,820
Estimated royalty obligations	3,940	4,000	'	'	'	3,700
Note at fair value	'	'	'	'	'	2,100
Assumption of liabilities	'	'	'	'	20	20
Total	'	'	'	'	'	$5,820

Note_2_Acquisitions_Details_VC

Note 2 - Acquisitions (Details) - VC Acquisition (USD $)	12 Months Ended
	Dec. 31, 2013	Jul. 08, 2013	Dec. 31, 2013	Jul. 31, 2013
		VeriTeQ Corporation [Member]	VeriTeQ Corporation [Member]	VeriTeQ Corporation [Member]
Note 2 - Acquisitions (Details) - VC Acquisition [Line Items]	'	'	'	'
Value of VC’s common stock outstanding on July 8, 2013 (1,029 shares @ $.90 per share)	'	'	'	$926,000
Value of VC’s stock options outstanding on July 8, 2013	400,000	9,000	'	'
Total	'	935,000	'	'
Assets purchased:	'	'	'	'
Cash	'	'	818,000	'
Marketable securities	'	'	239,000	'
Current portion of other receivable	'	'	168,000	'
Prepaid and other assets	'	'	47,000	'
Fixed assets	'	'	1,000	'
Other assets	'	'	60,000	'
Total	'	'	1,333,000	'
Liabilities assumed:	'	'	'	'
Accounts payable	'	'	72,000	'
Accrued expenses	'	'	326,000	'
Total	'	'	398,000	'
Net Assets Acquired	'	'	$935,000	'

Note_2_Acquisitions_Details_VC1

Note 2 - Acquisitions (Details) - VC Acquisition (Parentheticals) (USD $)	Dec. 31, 2013	Nov. 05, 2013	Oct. 18, 2013	Oct. 10, 2013	Oct. 05, 2013	Jul. 31, 2013	Jul. 12, 2013	Dec. 31, 2012	Jul. 31, 2013	Jul. 08, 2013	Jul. 31, 2013
									Common Stock [Member]	Common Stock [Member]	VeriTeQ Corporation [Member]
									VeriTeQ Corporation [Member]
Note 2 - Acquisitions (Details) - VC Acquisition (Parentheticals) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock outstanding	$0.01	'	$0.01	'	'	'	$0.01	$0.01	'	'	$1,029
Common stock share price	$2.29	$2	'	$2.10	$2.70	$1.50	'	'	$0.90	$0.90	'

Note_2_Acquisitions_Details_VC2

Note 2 - Acquisitions (Details) - VC Pro Forma Information (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
VC Pro Forma Information [Abstract]	'	'
Net operating revenue	$18	$0
Net loss	($18,577)	($3,958)
Net loss per common share – basic and diluted	-2.03	-0.52

Note_3_Intangible_Assets_Detai

Note 3 - Intangible Assets (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Note 3 - Intangible Assets (Details) [Line Items]	'	'
Amortization of Intangible Assets (in Dollars)	$0.60	$0.20
Acquired Intangible Assets [Member] | Minimum [Member]	'	'
Note 3 - Intangible Assets (Details) [Line Items]	'	'
Fair Value Inputs, Long-term Revenue Growth Rate	55.00%	'
Fair Value Inputs, Discount Rate	25.00%	'
Acquired Intangible Assets [Member] | Maximum [Member]	'	'
Note 3 - Intangible Assets (Details) [Line Items]	'	'
Fair Value Inputs, Long-term Revenue Growth Rate	358.00%	'
Fair Value Inputs, Discount Rate	45.00%	'

Note_3_Intangible_Assets_Detai1

Note 3 - Intangible Assets (Details) - Intangibles and Other Assets (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013
Note 3 - Intangible Assets (Details) - Intangibles and Other Assets [Line Items]	'	'
Intangible asset	$7,612	$7,018
Technology-Based Intangible Assets [Member]	'	'
Note 3 - Intangible Assets (Details) - Intangibles and Other Assets [Line Items]	'	'
Intangible asset	6,734	6,244
Intangible asset estimated useful life	'14 years	'
Customer Relationships [Member]	'	'
Note 3 - Intangible Assets (Details) - Intangibles and Other Assets [Line Items]	'	'
Intangible asset	431	359
Intangible asset estimated useful life	'7 years	'
Trademarks [Member]	'	'
Note 3 - Intangible Assets (Details) - Intangibles and Other Assets [Line Items]	'	'
Intangible asset	$447	$415
Intangible asset estimated useful life	'14 years	'

Note_3_Intangible_Assets_Detai2

Note 3 - Intangible Assets (Details) - Intangibles and Other Assets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Technology-Based Intangible Assets [Member]	'	'
Note 3 - Intangible Assets (Details) - Intangibles and Other Assets (Parentheticals) [Line Items]	'	'
Intangible asset, accumulated amortization	$627	$136
Customer Relationships [Member]	'	'
Note 3 - Intangible Assets (Details) - Intangibles and Other Assets (Parentheticals) [Line Items]	'	'
Intangible asset, accumulated amortization	141	69
Trademarks [Member]	'	'
Note 3 - Intangible Assets (Details) - Intangibles and Other Assets (Parentheticals) [Line Items]	'	'
Intangible asset, accumulated amortization	$35	$3

Note_3_Intangible_Assets_Detai3

Note 3 - Intangible Assets (Details) - Estimated Amortization of Intangible Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Estimated Amortization of Intangible Assets [Abstract]	'	'
2014	$594	'
2015	594	'
2016	594	'
2017	594	'
2018	594	'
Thereafter	4,048	'
	$7,018	$7,612

Note_4_Accrued_Expenses_Detail

Note 4 - Accrued Expenses (Details) - Significant Components of Accrued Expenses (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Significant Components of Accrued Expenses [Abstract]	'	'
Accrued payroll and payroll related	$1,734	$709
Accrued legal	445	291
Accrued other expenses	539	72
Total accrued expenses	$2,718	$1,072

Note_5_Notes_Payable_and_Restr2

Note 5 - Notes Payable and Restricted Cash (Details) (USD $)

0 Months Ended

12 Months Ended

25 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

Nov. 13, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Nov. 30, 2013

Apr. 03, 2014

Apr. 07, 2014

Apr. 03, 2014

Nov. 13, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 13, 2013

Nov. 21, 2013

Nov. 13, 2013

Dec. 31, 2013

Nov. 30, 2013

Nov. 13, 2013

Nov. 13, 2013

Dec. 31, 2013

Nov. 13, 2013

Nov. 30, 2013

Nov. 21, 2013

Nov. 30, 2013

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Net of Investor Expenses and Restricted Proceeds [Member]

Beneficial Conversion Feature [Member]

Beneficial Conversion Feature [Member]

Warrants Issued in Connection With Debt [Member]

Warrants Issued as Placement Agent Fee [Member]

Issuance Cost [Member]

Debt Discount Accretion [Member]

Shares Issued as Inducement to Convert Notes [Member]

Placement Agent [Member]

MGT Capital Investments Inc. [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Placement Agent [Member]

Investors and Placement Agent [Member]

Minimum [Member]

Proceeds from Financing [Member]

Proceeds from Financing [Member]

Proceeds from Sale of Marketable Securities [Member]

Proceeds from Sale of Marketable Securities [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Investors [Member]

Note 5 - Notes Payable and Restricted Cash (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,816,667

'

$1,816,667

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

166,667

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,650,000

'

'

'

'

'

'

'

'

'

Debt Instrument, Increase (Decrease), Other, Net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Debt

'

'

'

'

'

'

'

'

635,000

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,422,222

'

'

222,222

2,644,444

'

'

'

'

'

Debt Issuance Cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

115,000

'

'

'

'

'

'

'

'

'

Percent of Warrant Proceeds Placement Agent

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

222,222

'

'

'

'

'

'

Increase in Restricted Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

750,000

132,500

132,500

Sale of Stock, Number of Shares Issued in Transaction (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

Restricted Cash and Cash Equivalents

'

900,000

'

900,000

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Restricted Cash

'

882,000

'

882,000

'

145,000

-145,000

-145,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Agreement Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

Purchase Agreement Securities Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

Debt Instrument Default Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18.00%

'

'

'

'

'

'

'

'

Debt Conversion Beneficial Ownership Threshold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.75

'

'

'

'

'

'

'

'

Warrant Exercise Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.84

'

'

'

'

'

'

'

'

Interest Expense, Debt

'

$7,100,000

$100,000

'

'

'

'

'

'

$2,800,000

$31,000

$3,400,000

$400,000

$400,000

$300,000

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt, Weighted Average Interest Rate

'

'

37.62%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_5_Notes_Payable_and_Restr3

Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (USD $)	Dec. 31, 2013		Dec. 31, 2012
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Total notes payable	$467,000		$404,000
Less: Current maturities	467,000		326,000
Note payable long-term	'		78,000
Non-interest bearing subordinated convertible note payable with a principal amount of $3,300 dated December 3, 2012. Note is convertible into common stock equal to 1/3 of the shares beneficially held by the CEO on the date of conversion. Note was amended in July 2013 to extend the maturity date to June 2015. The note was recorded at its fair value and will be revalued at each reporting period with changes in the fair value recorded as other expense/income.	4,925,000		2,137,000
Chief Executive Officer [Member] | Demand Note October 11, 2013 [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Note payable	30,000	[1]	'	[1]
Chief Executive Officer [Member] | Demand Note October 29, 2013 [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Note payable	30,000	[1]	'	[1]
Convertible Note September 25, 2012 [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Convertible note	'	[2]	94,000	[2]
Convertible Note October 12, 2012 [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Convertible note	'	[1],[2]	86,000	[1],[2]
Convertible Note December 31, 2012 A [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Convertible note	'	[1],[2]	45,000	[1],[2]
Convertible Note December 31, 2012 B [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Convertible note	'	[1],[2]	22,000	[1],[2]
Secured Debt [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Convertible note	232,000	[2]	'	[2]
PositiveID [Member]	'		'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt [Line Items]	'		'
Note payable	$175,000	[2],[3]	$157,000	[2],[3]
[1]	These notes have been issued to related parties. For additional discussion, see Note 10.
[2]	The warrants are more fully described in Note 7.
[3]	This note when originally issued was issued to a related party. See Note 10 for additional discussion.

Note_5_Notes_Payable_and_Restr4

Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Chief Executive Officer [Member] | Demand Note October 11, 2013 [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	$80,000	'
Interest	5.00%	'
Chief Executive Officer [Member] | Demand Note October 29, 2013 [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	30,000	'
Interest	5.00%	'
Additional Warrants Issued As Inducement [Member] | Convertible Note September 25, 2012 [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Warrants (in Shares)	40,000	'
Warrants exercise price (in Dollars per share)	$1.57	'
Additional Warrants Issued As Inducement [Member] | Convertible Note October 12, 2012 [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Warrants (in Shares)	40,000	'
Warrants exercise price (in Dollars per share)	$1.57	'
Additional Warrants Issued As Inducement [Member] | Convertible Note December 31, 2012 A [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Warrants (in Shares)	29,000	'
Warrants exercise price (in Dollars per share)	$1.57	'
Additional Warrants Issued As Inducement [Member] | Convertible Note December 31, 2012 B [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Warrants (in Shares)	14,000	'
Warrants exercise price (in Dollars per share)	$1.57	'
Convertible Note September 25, 2012 [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	'	125,000
Interest	'	10.00%
Discount	'	31,000
Conversion price (in Dollars per share)	'	$1.57
Warrants (in Shares)	'	40,000
Warrants exercise price (in Dollars per share)	'	$1.57
Convertible Note October 12, 2012 [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	'	125,000
Interest	'	10.00%
Discount	'	39,000
Conversion price (in Dollars per share)	'	$1.57
Warrants (in Shares)	'	40,000
Warrants exercise price (in Dollars per share)	'	$1.57
Convertible Note December 31, 2012 A [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	'	100,000
Interest	'	10.00%
Discount	'	55,000
Conversion price (in Dollars per share)	'	$1.57
Warrants (in Shares)	'	29,000
Warrants exercise price (in Dollars per share)	'	$1.57
Convertible Note December 31, 2012 B [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	'	50,000
Interest	'	10.00%
Discount	'	28,000
Conversion price (in Dollars per share)	'	$1.57
Warrants (in Shares)	'	14,000
Warrants exercise price (in Dollars per share)	'	$1.57
Secured Debt [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	1,817,000	'
Discount	1,585,000	'
Conversion price (in Dollars per share)	$0.75	'
Warrants (in Shares)	2,644,000	'
Warrants exercise price (in Dollars per share)	$2.84	'
Subordinated Debt [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	3,300,000	3,300,000
PositiveID [Member]	'	'
Note 5 - Notes Payable and Restricted Cash (Details) - Notes Payable and Long-term Debt (Parentheticals) [Line Items]	'	'
Note face amount	200,000	200,000
Interest	5.00%	5.00%
Discount	$0	$43,000

Note_5_Notes_Payable_and_Restr5

Note 5 - Notes Payable and Restricted Cash (Details) - Maturities of Current and Long-term Debt (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Maturities of Current and Long-term Debt [Abstract]	'
2014	$1,877	[1]
2015	3,300
Total payments	$5,177
[1]	The PSID Note, which has been assigned to various investors, is only convertible into stock and, thus, is not included in the scheduled payments due in 2014 in the table above.

Note_6_Financial_Instruments_D

Note 6 - Financial Instruments (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2013		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified		Warrant [Member]		Embedded Conversion Option Of Notes [Member]	Convertible Subordinated Debt [Member]	Estimated Royalty Obligations [Member]	Estimated Royalty Obligations [Member]
						Minimum [Member]	Maximum [Member]
Note 6 - Financial Instruments (Details) [Line Items]	'	'		'	'	'	'
Fair Value Inputs, Discount Rate	'	'		'	22.80%	25.00%	60.00%
Fair Value Assumptions, Expected Term	'	'4 years 317 days		'335 days	'	'3 years	'14 years
Fair Value Assumptions, Expected Volatility Rate	'	155.00%		0.18%	'	'	'
Fair Value Assumptions, Risk Free Interest Rate	'	1.75%		'	'	'	'
Fair Value Assumptions, Expected Dividend Rate	'	0.00%		'	'	'	'
Fair Value Assumptions, Market Price (in Dollars per share)	'	'		$2.29	'	'	'
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	'	'		$0.75	'	'	'
Accrued Royalties (in Dollars)	$60	$6,114	[1]	'	'	'	'
[1]	Includes $60 thousand of current royalty obligations included in accrued expenses at December 31, 2013.

Note_6_Financial_Instruments_D1

Note 6 - Financial Instruments (Details) - Assets and Liabilities Measured at Fair Value (USD $)	Dec. 31, 2013	Dec. 31, 2012
Liabilities:	'	'
Subordinated convertible note with an embedded conversion option	$4,925,000	$2,137,000
Royalty obligations	3,940,000	4,000,000
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities:	'	'
Warrant liabilities	6,114,000	'
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities:	'	'
Subordinated convertible note with an embedded conversion option	4,925,000	2,137,000
Conversion option of the Notes	3,124,000	'
Royalty obligations	$4,000,000	$4,000,000

Note_6_Financial_Instruments_D2

Note 6 - Financial Instruments (Details) - Level 3 Liabilities Activity (USD $)	0 Months Ended		12 Months Ended		25 Months Ended
	Dec. 31, 2013		Dec. 31, 2013		Dec. 31, 2013		Dec. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'		'		'		'
Subordinated note with convertible option	$4,925,000		$4,925,000		$4,925,000		$2,137,000
Estimated royalty obligations	60,000		60,000		60,000		'
Initial fair value of conversion option of the Notes	4,925,000		4,925,000		4,925,000		2,137,000
Issuances of warrants accounted for as liabilities	3,100,000		363,000		363,000		'
Change in fair value	'		-720,000		-720,000		'
Warrant [Member]	'		'		'		'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'		'		'		'
Estimated royalty obligations	6,114,000	[1]	6,114,000	[1]	6,114,000	[1]	'
Issuances of warrants accounted for as liabilities	'		5,394,000		'		'
Change in fair value	'		720,000		'		'
Convertible Debt [Member]	'		'		'		'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'		'		'		'
Subordinated note with convertible option	2,761		2,761		2,761		'
Warrant liabilities	3,124		3,124		3,124		'
Initial fair value of conversion option of the Notes	2,761		2,761		2,761		'
Change in fair value	'		363		'		'
Convertible Subordinated Debt [Member]	'		'		'		'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'		'		'		'
Subordinated note with convertible option	4,925,000		4,925,000		4,925,000		2,137,000
Initial fair value of conversion option of the Notes	4,925,000		4,925,000		4,925,000		2,137,000
Change in fair value	'		$2,788,000		'		'
[1]	Includes $60 thousand of current royalty obligations included in accrued expenses at December 31, 2013.

Note_7_Stockholders_Deficit_De

Note 7 - Stockholders' Deficit (Details) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

180 Months Ended

132 Months Ended

12 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

Oct. 18, 2013

Jul. 12, 2013

Jul. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 05, 2013

Oct. 10, 2013

Oct. 05, 2013

Oct. 10, 2013

Oct. 18, 2013

Oct. 10, 2013

Oct. 18, 2013

Dec. 31, 2013

Jul. 08, 2013

Oct. 18, 2013

Jul. 12, 2013

Oct. 17, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

Beneficial Owner [Member]

Series B Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series B, C, D, E, F, G and H Warrants [Member]

Restricted Stock [Member]

1999 Flexible Stock Plan [Member]

1999 Flexible Stock Plan [Member]

1999 Employees' Stock Plan [Member]

2003 Flexible Stock Plan [Member]

Digital Angel Transition Stock Option Plan [Member]

DAC 2013 Stock Incentive Plan [Member]

Outside of Plans [Member]

Investor Relation Firm [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Chief Executive Officer [Member]

1999 Flexible Stock Plan [Member]

1999 Employees' Stock Plan [Member]

2003 Flexible Stock Plan [Member]

Digital Angel Transition Stock Option Plan [Member]

1999 Flexible Stock Plan [Member]

1999 Employees' Stock Plan [Member]

2003 Flexible Stock Plan [Member]

Digital Angel Transition Stock Option Plan [Member]

July Letter Agreement [Member]

July Letter Agreement [Member]

July Letter Agreement [Member]

July Letter Agreement [Member]

To Be Issued As Soon As Possible Thereafter [Member]

To Be Issued As Soon As Possible Thereafter [Member]

Note 7 - Stockholders' Deficit (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

4,107,592

'

410,759

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Ratio

20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$0.01

$0.01

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

'

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

500,000

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,215,184

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of Converted Issued and Outstanding Common Stock

88.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

41,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

163,333

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services (in Dollars)

'

'

$62,500

'

$160,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$400,000

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

$1.50

$2.29

'

$2

$2.10

$2.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity Note, Stock Split, Conversion Ratio

30

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

135,793

135,793

16,666

16,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

'

'

50,000,000

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

'

'

9,459,000

7,021,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding

9,302,674

'

'

9,459,000

7,021,000

'

'

'

'

'

'

'

5,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding (in Dollars)

'

'

'

6,114,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Non-cash Interest Expense (in Dollars)

'

'

'

300,000

31,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years

'6 years

'6 years

'

'10 years

'10 years

'10 years

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

15,000

5,400

133,000

61,000

5,000,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,000

4,200

93,000

40,000

'

4,400

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

'

'

'

2,628,000

1,531,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700

1,700

1,100

29,000

30,000

2,600,000

4,000

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

2,503,000

1,684,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

1,000

1,200

41,000

21,000

2,400,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'3 years

'3 years

'

'

'10 years

'9 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

1,050,000

458,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

'

'

'

$1.33

$0.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

'

'

126.00%

126.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

'

'

0.83%

0.67%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense (in Dollars)

'

'

'

1,400,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)

'

'

'

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value (in Dollars)

'

'

'

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'6 years 98 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'5 years 149 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross

'

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Restricted Stock Award, Gross (in Dollars)

'

'

'

$1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_7_Stockholders_Deficit_De1

Note 7 - Stockholders' Deficit (Details) - Warrants Exercisable (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'
Warrants Authorized	3,380
Warrants Issued	3,380
Balance (in Dollars)	$3,380
Series A Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	95
Warrants Issued	95
Balance (in Dollars)	95
Exercise Price (in Dollars per share)	$0.37
Exercisable Period	'3 years
Series B Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	40
Warrants Issued	40
Balance (in Dollars)	40
Exercise Price (in Dollars per share)	$1.57
Exercisable Period	'3 years
Series C Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	40
Warrants Issued	40
Balance (in Dollars)	40
Exercise Price (in Dollars per share)	$1.57
Exercisable Period	'3 years
Series D Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	14
Warrants Issued	14
Balance (in Dollars)	14
Exercise Price (in Dollars per share)	$1.57
Exercisable Period	'5 years
Series E Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	29
Warrants Issued	29
Balance (in Dollars)	29
Exercise Price (in Dollars per share)	$1.57
Exercisable Period	'5 years
Series F Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	40
Warrants Issued	40
Balance (in Dollars)	40
Exercise Price (in Dollars per share)	$1.57
Exercisable Period	'3 years
Series G Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	95
Warrants Issued	95
Balance (in Dollars)	95
Exercise Price (in Dollars per share)	$1.31
Exercisable Period	'3 years
Series H Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	83
Warrants Issued	83
Balance (in Dollars)	83
Exercise Price (in Dollars per share)	$1.57
Exercisable Period	'3 years
Series VT a Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	2,644
Warrants Issued	2,644
Balance (in Dollars)	2,644
Exercise Price (in Dollars per share)	$2.84
Exercisable Period	'5 years
Series VT b Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Authorized	300
Warrants Issued	300
Balance (in Dollars)	$300
Exercise Price (in Dollars per share)	$2.84
Exercisable Period	'5 years

Note_7_Stockholders_Deficit_De2

Note 7 - Stockholders' Deficit (Details) - Fair Value of Warrants Assumptions (Warrant [Member])	0 Months Ended					1 Months Ended
	Nov. 13, 2013	Jun. 02, 2013	Apr. 10, 2013	Oct. 12, 2012	Jun. 02, 2012	Mar. 18, 2013	Dec. 31, 2012	Sep. 25, 2012
Warrant [Member]	'	'	'	'	'	'	'	'
Note 7 - Stockholders' Deficit (Details) - Fair Value of Warrants Assumptions [Line Items]	'	'	'	'	'	'	'	'
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Volatility	154.00%	126.00%	126.00%	126.00%	126.00%	126.00%	126.00%	126.00%
Expected lives	'5 years	'3 years	'3 years	'3 years	'3 years	'3 years	'5 years	'3 years
Risk-free rate	1.41%	0.52%	0.34%	0.35%	0.34%	0.38%	0.72%	0.35%

Note_7_Stockholders_Deficit_De3

Note 7 - Stockholders' Deficit (Details) - Stock Option Activity (USD $)	12 Months Ended				0 Months Ended	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Jan. 11, 2012	Dec. 31, 2012	Dec. 31, 2013
					PositiveID Animal Health Corporation [Member]	PositiveID Animal Health Corporation [Member]	VC Acquisition [Member]
Note 7 - Stockholders' Deficit (Details) - Stock Option Activity [Line Items]	'		'		'	'	'
Outstanding on January 1	1,531,000		'		'	'	'
Outstanding on January 1 (in Dollars per share)	$0.31	[1]	'		'	'	'
Granted	1,050,000		458,000		'	'	'
Granted (in Dollars per share)	$1.57		$1.05		'	'	'
Assumed in acquisition	'		'		6,900,000	1,307,000	75,000
Assumed in acquisition, weighted average exercise price (in Dollars per share)	'		'		'	$0.05	$344.15
Forfeited or expired	-28,000		-234,000		'	'	'
Forfeited or expired (in Dollars per share)	$151.64		$0.31		'	'	'
Outstanding at December 31	2,628,000		1,531,000		'	'	'
Outstanding at December 31 (in Dollars per share)	$9.01		$0.31	[1]	'	'	'
Exercisable at December 31(1)	1,579,000	[1]	1,264,000	[1]	'	'	'
Exercisable at December 31(1) (in Dollars per share)	$13.95	[1]	$0.05	[1]	'	'	'
Vested or expected to vest at December 31(2)	2,628,000	[2]	1,531,000	[2]	'	'	'
Vested or expected to vest at December 31(2) (in Dollars per share)	$9.01	[2]	$0.31	[1],[2]	'	'	'
Shares available on December 31 for options that may be granted	2,503,000		1,684,000		'	'	'
[1]	The intrinsic value of a stock option is the amount by which the fair value of the underlying stock exceeds the exercise price of the option. The fair value of our common stock was $2.29 at December 31, 2013 based upon the closing price on the OTC Market. As of December 31, 2013, the aggregate intrinsic value of options outstanding, exercisable and vested or expected to vest was $3.8 million, $3.0 million and $3.8 million, respectively.
[2]	The weighted average remaining contractual life for exercisable options is 6.27 years, and for options vested or expected to vest, is 5.41 years, as of December 31, 2013.

Note_7_Stockholders_Deficit_De4

Note 7 - Stockholders' Deficit (Details) - Stock Option Exercise Price Range (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Outstanding shares (in Shares)	2,628
Outstanding weighted average remaining contractual life in years	'5 years 146 days
Outstanding weighted average exercise price	$9.01
Exercisable shares (in Shares)	1,579
Exercisable weighted average exercise price	$13.95
Range 1 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$0
Exercise price range, upper limit	$100
Outstanding shares (in Shares)	2,593
Outstanding weighted average remaining contractual life in years	'5 years 6 months
Outstanding weighted average exercise price	$1.03
Exercisable shares (in Shares)	1,544
Exercisable weighted average exercise price	$0.66
Range 2 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$101
Exercise price range, upper limit	$200
Outstanding shares (in Shares)	5
Outstanding weighted average remaining contractual life in years	'4 years 73 days
Outstanding weighted average exercise price	$156.71
Exercisable shares (in Shares)	5
Exercisable weighted average exercise price	$156.71
Range 3 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$201
Exercise price range, upper limit	$300
Outstanding shares (in Shares)	1
Outstanding weighted average remaining contractual life in years	'3 years 219 days
Outstanding weighted average exercise price	$244.80
Exercisable shares (in Shares)	1
Exercisable weighted average exercise price	$244.80
Range 4 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$301
Exercise price range, upper limit	$400
Outstanding shares (in Shares)	1
Outstanding weighted average remaining contractual life in years	'2 years 219 days
Outstanding weighted average exercise price	$342.29
Exercisable shares (in Shares)	1
Exercisable weighted average exercise price	$342.29
Range 5 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$401
Exercise price range, upper limit	$500
Outstanding weighted average remaining contractual life in years	'2 years 6 months
Outstanding weighted average exercise price	$451.20
Exercisable weighted average exercise price	$451.20
Range 6 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$501
Exercise price range, upper limit	$600
Outstanding shares (in Shares)	11
Outstanding weighted average remaining contractual life in years	'1 year 292 days
Outstanding weighted average exercise price	$568.39
Exercisable shares (in Shares)	11
Exercisable weighted average exercise price	$568.39
Range 7 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$601
Exercise price range, upper limit	$700
Outstanding shares (in Shares)	5
Outstanding weighted average remaining contractual life in years	'73 days
Outstanding weighted average exercise price	$661.82
Exercisable shares (in Shares)	5
Exercisable weighted average exercise price	$661.82
Range 8 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$701
Exercise price range, upper limit	$800
Outstanding shares (in Shares)	1
Outstanding weighted average remaining contractual life in years	'1 year 255 days
Outstanding weighted average exercise price	$733.38
Exercisable shares (in Shares)	1
Exercisable weighted average exercise price	$733.38
Range 9 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$801
Exercise price range, upper limit	$900
Outstanding shares (in Shares)	9
Outstanding weighted average remaining contractual life in years	'1 year 73 days
Outstanding weighted average exercise price	$871.20
Exercisable shares (in Shares)	9
Exercisable weighted average exercise price	$871.20
Range 10 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price range, lower limit	$901
Exercise price range, upper limit	$1,000
Outstanding shares (in Shares)	2
Outstanding weighted average remaining contractual life in years	'255 days
Outstanding weighted average exercise price	$966.93
Exercisable shares (in Shares)	2
Exercisable weighted average exercise price	$966.93

Note_8_Income_Taxes_Details

Note 8 - Income Taxes (Details) (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jul. 08, 2013	Dec. 31, 2013
				Internal Revenue Service (IRS) [Member]	Internal Revenue Service (IRS) [Member]
				Limited Under IRC Section 382 [Member]
Note 8 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Income Tax Expense (Benefit)	$0	($800,000)	($800,000)	'	'
Deferred Tax Assets, Valuation Allowance	2,905,000	152,000	2,905,000	'	'
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	2,800,000	200,000	'	'	'
Operating Loss Carryforwards	'	'	'	500,000	5,100,000
Unrecognized Tax Benefits	$0	$0	$0	'	'

Note_8_Income_Taxes_Details_Be

Note 8 - Income Taxes (Details) - Benefit (Provision) for Income Taxes (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Benefit (Provision) for Income Taxes [Abstract]	'	'	'
Deferred income taxes benefit	'	$800,000	$800,000
Total income tax benefit	$0	$800,000	$800,000

Note_8_Income_Taxes_Details_De

Note 8 - Income Taxes (Details) - Deferred Tax Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Accrued compensation and stock-based compensation	$1,580	$401
Net operating loss carryforwards	1,961	454
Gross deferred tax assets	3,541	855
Valuation allowance	-2,905	-152
Deferred tax liabilities:	'	'
Amortization of intangible assets	-636	-703
Gross deferred tax liabilities	($636)	($703)

Note_8_Income_Taxes_Details_In

Note 8 - Income Taxes (Details) - Income Tax Reconciliation	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Reconciliation [Abstract]	'	'
Statutory tax/(benefit) rate	-35.00%	-35.00%
State income taxes, net of federal benefits	-4.00%	-4.00%
Transaction costs not deductible	1.00%	'
Interest and other expenses not deductible	23.00%	'
Change in deferred tax asset valuation allowance	15.00%	6.00%
	'	-33.00%

Note_9_Loss_Per_Share_Details_

Note 9 - Loss Per Share (Details) - Basic and Diluted (Loss) Income Per Share (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Numerator for basic and diluted loss per share:	'		'
Loss from continuing operations	($18,201)		($1,605)
Denominator for basic and diluted loss per share:	'		'
Basic and diluted weighted-average shares outstanding (1)(2)	8,607	[1],[2]	6,529	[1],[2]
Loss per share — basic and diluted	'		'
Total — basic and diluted	($2.11)		($0.25)
[1]	Basic and diluted loss per common share has been computed by dividing the loss by the weighted average number of common shares outstanding.
[2]	The following stock options and warrants and shares issuable upon conversion of convertible notes payable outstanding at December 31, 2013 and 2012 were not included in the computation of dilutive loss per share because the net effect would have been anti-dilutive:

Note_9_Loss_Per_Share_Details_1

Note 9 - Loss Per Share (Details) - Antidilutive Securities	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	10,717	4,057
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	2,628	1,531
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	3,380	218
Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	4,709	2,308

Note_10_Related_Party_Transact1

Note 10 - Related Party Transactions (Details) (USD $)

Nov. 08, 2013

Oct. 10, 2013

Oct. 18, 2013

Oct. 10, 2013

Oct. 18, 2013

Sep. 02, 2012

Jun. 02, 2012

Jun. 25, 2012

Jan. 12, 2012

Nov. 08, 2013

Nov. 08, 2013

Nov. 08, 2013

Nov. 08, 2013

Nov. 08, 2013

Jul. 08, 2013

Sep. 30, 2013

Apr. 22, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID Animal Health Corporation [Member]

PositiveID [Member]

PositiveID [Member]

Veriteq Acquisition Corporation [Member]

Veriteq Acquisition Corporation [Member]

Accrued Expenses [Member]

Accrued Expenses [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Shared Services Agreement [Member]

Shared Services Agreement [Member]

Shared Services Agreement [Member]

Shared Services Agreement [Member]

November Letter Agreement [Member]

November Letter Agreement [Member]

November Letter Agreement [Member]

November Letter Agreement [Member]

November Letter Agreement [Member]

Notes Payable, Other Payables [Member]

Shared Services Agreement [Member]

Shared Services Agreement [Member]

Equity Investment [Member]

July Letter Agreement [Member]

July Letter Agreement [Member]

July Letter Agreement [Member]

July Letter Agreement [Member]

Due 30 Days After Initial Payment [Member]

Due 60 Days After Initial Payment [Member]

Total Due After Initial Payment [Member]

Defualt Interest Rate [Member]

To Be Issued As Soon As Possible Thereafter [Member]

To Be Issued As Soon As Possible Thereafter [Member]

Note 10 - Related Party Transactions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment, Principal

'

'

'

'

'

$5,000

$12,000

'

$30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Required Financing Proceeds Required For Payment Activation

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due from Related Parties, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

Minimum Capital Investment Raise Proceeds Required To Activate Payment

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due to Related Parties, Current

'

'

'

'

'

'

'

'

'

50,000

100,000

100,000

'

100,000

'

'

'

'

'

'

'

1,600,000

700,000

Related Party Transaction, Rate

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

Minimum Level of Royalty Payments

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Related Parties

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

228,000

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.84

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

135,793

135,793

16,666

16,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due to Related Parties

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

100,000

'

'

'

'

Related Party Transaction, Amounts of Transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

'

'

'

Conversion of Stock, Shares Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,084

'

'

Note_11_Commitments_and_Contin2

Note 11 - Commitments and Contingencies (Details)

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

Share data in Millions, unless otherwise specified

Mar. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 08, 2013

Dec. 31, 2013

Jul. 08, 2013

Jan. 30, 2014

Jul. 08, 2013

Jan. 02, 2012

Jan. 02, 2013

Jul. 08, 2013

Jan. 30, 2014

Dec. 31, 2014

Jul. 08, 2013

Jan. 02, 2013

USD ($)

GBP (£)

USD ($)

USD ($)

USD ($)

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

President [Member]

President [Member]

President [Member]

President [Member]

President [Member]

President [Member]

Silverman Contractual Obligation [Member]

Silverman Contractual Obligation [Member]

Subsequent Event [Member]

USD ($)

USD ($)

Restricted Stock [Member]

Geissler Contractual Obligations [Member]

Subsequent Event [Member]

Scenario, Forecast [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Note 11 - Commitments and Contingencies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense

'

'

$77,000

$11,000

'

'

'

'

'

'

'

'

'

'

'

'

Officers' Compensation

'

'

'

'

'

'

'

'

330,000

300,000

'

'

'

210,000

200,000

200,000

Officer Compensation Annual Increase

'

'

'

'

'

'

'

'

5.00%

10.00%

'

'

'

'

5.00%

'

Annual Non-allocable Expense Payment

'

'

'

'

'

'

'

'

30,000

45,000

'

'

'

'

'

'

Reimbursement of Disability Insurance

'

'

'

'

'

'

'

'

22,500

'

'

'

'

'

15,000

'

Reimbursement of Health Benefits

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

Reimbursement of Business Attire Expense

'

'

'

'

'

'

'

'

950

'

'

'

'

'

950

'

Accrued Bonuses

'

'

'

'

'

'

'

100,000

'

'

'

'

75,000

'

'

'

Contingent Bonus Increase

'

'

'

'

'

'

'

25.00%

'

'

'

'

25.00%

'

'

'

Contractual Obligation

'

'

'

'

'

'

912,116

'

'

'

'

166,666

'

'

'

'

Minimum Capital Investment Raise Proceeds Required To Activate Payment

'

'

'

'

3,000,000

'

3,000,000

'

'

'

'

3,000,000

'

'

'

'

Payments to Employees

'

'

'

'

'

66,000

'

'

'

'

'

'

'

'

'

'

Change of Control Provision Payment Base Salary Rate

'

'

'

'

'

'

'

'

299.00%

'

'

'

'

'

'

'

Change of Control Provision Payment Bonus Rate

'

'

'

'

'

'

'

'

299.00%

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)

'

'

'

'

'

'

'

'

'

'

4.5

'

'

'

'

'

Minimum Capital Investment From Third Party To Activate Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

Termination Payment Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

Portion of Purchase Price From Sale of Division to Satisfy Outstanding Liabilities

61,000

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Third Party Claim to Liquidator

$400,000

£ 244,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_11_Commitments_and_Contin3

Note 11 - Commitments and Contingencies (Details) - Minimum Payments Required Under Operating Leases and Employment Contracts (USD $)	Dec. 31, 2013
Note 11 - Commitments and Contingencies (Details) - Minimum Payments Required Under Operating Leases and Employment Contracts [Line Items]	'
2014	$48,000
2015	47,000
2016	40,000
2017	42,000
2018	17,000
	194,000
Employment Contract [Member]	'
Note 11 - Commitments and Contingencies (Details) - Minimum Payments Required Under Operating Leases and Employment Contracts [Line Items]	'
2014	1,229,000
2015	1,285,000
2016	1,343,000
	$3,857,000

Note_13_Supplemental_Cash_Flow2

Note 13 - Supplemental Cash Flow Information (Details) - Supplemental Cash Flow Information (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Non-cash investing and financing activities:	'	'
Acquisition of assets for common stock, assumption of stock options and a promissory note	'	$1,200
Notes and accrued interest related to notes converted into common stock	420	'
Issuance of common stock in partial payment of notes payable	25	'
Shared Services Payment with PSID [Member]	'	'
Non-cash operating activities:	'	'
Issuance of shares of common stock to settle the partial payment of payable under a shared services agreement with PSID	'	160
VC Acquisition [Member]	'	'
Non-cash investing and financing activities:	'	'
Net assets acquired from VC in excess of cash acquired for common stock	$117	'

Note_14_Restatement_and_Amendm2

Note 14 - Restatement and Amendment of Previously Reported Financial Statements (Details) (USD $)	0 Months Ended	12 Months Ended	25 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Nov. 30, 2013	Nov. 13, 2013
				Investors [Member]	Investors [Member]	Investors [Member]
Note 14 - Restatement and Amendment of Previously Reported Financial Statements (Details) [Line Items]	'	'	'	'	'	'
Convertible Notes Payable	'	'	'	'	$1,816,667	$1,816,667
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	'	'	'	$0.75	'	'
Increase (Decrease) in Derivative Liabilities	$3,100,000	$363,000	$363,000	'	'	'

Note_14_Restatement_and_Amendm3

Note 14 - Restatement and Amendment of Previously Reported Financial Statements (Details) - Effect of Restatement on Financial Statements (USD $)	0 Months Ended	1 Months Ended	12 Months Ended				25 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013
LIABILITIES AND STOCKHOLDERS’ DEFICIT	'	'	'		'		'
Liabilities for conversion option under convertible notes	$3,124	'	$3,124		$0		$3,124
Total current liabilities	7,374	'	7,374		1,618		7,374
Total liabilities	22,353	'	22,353		7,833		22,353
Accumulated deficit during the development stage	-19,824	'	-19,824		-1,623		-19,824
Total stockholders’ deficit	-14,134	-18	-14,134		-38		-14,134
Other expense	'	'	4,527		'		4,527
Interest expense	'	'	7,096		133		7,229
Loss before income taxes	'	'	-18,201		-2,405		-20,624
Net loss	'	-18	-18,201		-1,605		-19,824
Non-cash interest expense	'	'	6,634		118		6,752
Change in fair value of conversion option under convertible notes	3,100	'	363		'		363
Net loss	'	'	-18,577		-3,958		'
Net loss per common share – basic and diluted (in Dollars per share)	'	'	($2.03)		'		'
Comprehensive loss	'	'	-18,201	[1]	-1,605	[1]	-19,824	[1]
Net loss per common share — basic and diluted (in Dollars per share)	'	'	($2.11)		($0.25)		'
Scenario, Previously Reported [Member]	'	'	'		'		'
LIABILITIES AND STOCKHOLDERS’ DEFICIT	'	'	'		'		'
Liabilities for conversion option under convertible notes	0	'	0		'		0
Total current liabilities	4,250	'	4,250		'		4,250
Total liabilities	19,229	'	19,229		'		19,229
Accumulated deficit during the development stage	-16,700	'	-16,700		'		-16,700
Total stockholders’ deficit	-11,010	'	-11,010		'		-11,010
Other expense	'	'	4,164		'		4,164
Interest expense	'	'	4,335		'		4,468
Loss before income taxes	'	'	-15,077		'		-17,500
Net loss	'	'	-15,077		'		-16,700
Non-cash interest expense	'	'	3,873		'		3,991
Change in fair value of conversion option under convertible notes	'	'	0		'		'
Net loss	'	'	-15,453		'		'
Net loss per common share – basic and diluted (in Dollars per share)	'	'	($1.69)		'		'
Comprehensive loss	'	'	-15,077		'		-16,700
Net loss per common share — basic and diluted (in Dollars per share)	'	'	($1.75)		'		'
Scenario, Adjustment [Member]	'	'	'		'		'
LIABILITIES AND STOCKHOLDERS’ DEFICIT	'	'	'		'		'
Liabilities for conversion option under convertible notes	3,124	'	3,124		'		3,124
Total current liabilities	3,124	'	3,124		'		3,124
Total liabilities	3,124	'	3,124		'		3,124
Accumulated deficit during the development stage	-3,124	'	-3,124		'		-3,124
Total stockholders’ deficit	-3,124	'	-3,124		'		-3,124
Other expense	'	'	363		'		363
Interest expense	'	'	2,761		'		2,761
Loss before income taxes	'	'	-3,124		'		-3,124
Net loss	'	'	-3,124		'		-3,124
Non-cash interest expense	'	'	2,761		'		2,761
Change in fair value of conversion option under convertible notes	'	'	363		'		363
Net loss	'	'	-3,124		'		'
Net loss per common share – basic and diluted (in Dollars per share)	'	'	($0.34)		'		'
Comprehensive loss	'	'	($3,124)		'		($3,124)
Net loss per common share — basic and diluted (in Dollars per share)	'	'	($0.36)		'		'
[1]	During the quarter ended December 31, 2013, we reclassified $54 thousand related to the unrealized loss on of marketable securities held for sale from otheraccumulated comprehensive loss to net loss as a result of the sale of the marketable securities in November 2013.

Note_15_Subsequent_Events_Deta

Note 15 - Subsequent Events (Details)

12 Months Ended

25 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Jan. 31, 2014

Jan. 08, 2014

Jan. 31, 2014

Jan. 15, 2014

Jul. 08, 2013

Jan. 02, 2013

Apr. 07, 2014

Jan. 15, 2014

Jul. 08, 2013

Jan. 02, 2012

Mar. 04, 2014

Mar. 10, 2014

Mar. 10, 2014

Jan. 31, 2014

Jan. 31, 2014

Mar. 31, 2014

Feb. 14, 2014

Mar. 06, 2014

Mar. 05, 2014

Mar. 20, 2014

Mar. 06, 2014

Mar. 05, 2014

Apr. 03, 2014

Apr. 07, 2014

Apr. 03, 2014

Apr. 15, 2014

Dec. 31, 2013

Nov. 13, 2013

USD ($)

USD ($)

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

President [Member]

President [Member]

President [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Director [Member]

William Caragol [Member]

William Caragol [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Investors [Member]

Investors [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

USD ($)

USD ($)

Subsequent Event [Member]

Subsequent Event [Member]

USD ($)

USD ($)

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Digital Angel Radio Communications, Inc. [Member]

Digital Angel Radio Communications, Inc. [Member]

Digital Angel Radio Communications, Inc. [Member]

Corbin Properties LLC [Member]

James Rybicki Trust [Member]

James Rybicki Trust [Member]

Deephaven Enterprises, Inc. [Member]

Deephaven Enterprises, Inc. [Member]

Deephaven Enterprises, Inc. [Member]

Investors [Member]

Investors [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Minimum [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Chief Executive Officer [Member]

USD ($)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Note 15 - Subsequent Events (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employment Term

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employment Renewal Term

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Officers' Compensation

'

'

$210,000

'

'

'

$200,000

$200,000

'

'

$330,000

$300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Officer Compensation Annual Increase

'

'

5.00%

'

'

'

5.00%

'

'

'

5.00%

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement of Disability Insurance

'

'

15,000

'

'

'

15,000

'

'

'

22,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Automobile Reimbursement Percentage

'

'

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual Bonus Salary Percentage

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Consideration Transferred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

62,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on Contract Termination

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

52,000

'

'

'

'

'

'

'

'

'

'

'

'

Due to Related Parties

'

'

'

60,000

'

40,000

'

'

51,500

60,000

'

'

25,000

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

5.00%

'

5.00%

'

'

'

5.00%

'

'

5.00%

9.00%

'

'

'

'

10.00%

9.00%

'

9.00%

'

9.00%

'

'

'

'

'

'

Repayments of Related Party Debt

'

'

'

'

'

'

'

'

8,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

175,000

'

25,000

61,225

25,000

'

'

'

'

'

'

1,650,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.35

'

'

'

$0.35

'

'

'

'

$0.75

'

Conversion Price Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

2,422,222

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.35

'

'

'

'

'

'

$2.84

'

Increase (Decrease) in Restricted Cash

882,000

882,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

145,000

-145,000

-145,000

'

'

'

Restricted Cash and Investments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$700,000

'

'